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WHOLE GENOME SEQUENCING TO IDENTIFY FAMILIAL WILMS TUMOR 
PREDISPOSITION GENES 
 
 
Timothy Blake Palculict 
 
Advisory Professor: Vicki Huff, Ph.D. 
 
 
 Wilms tumor, a childhood tumor arising from undifferentiated renal 
mesenchyme, is diagnosed in North America at a frequency of 1 in 10,000 live births 
and accounts for 5% of all pediatric cancers. The etiology of Wilms tumor is 
heterogeneous with multiple genes known to have an effect on Wilms tumor 
development; however, these genes are rarely associated with familial Wilms tumor. 
Gene mutations in WT1, WTX, CTNNB1 and TP53 are observed in a third of sporadic 
tumors, while the causative gene(s) responsible for familial Wilms tumor are largely 
unknown. Approximately 2% of Wilms tumor patients have a family history of Wilms 
tumor.  Familial predisposition is inherited in an autosomal dominant manner and 
demonstrates incomplete penetrance, estimated to be 30%.  
Whole genome sequencing of eleven individuals in three Wilms tumor families 
was performed to identify the gene(s) responsible for genetic predisposition to Wilms 
tumor in these families, and to increase our understanding of a genetically 
heterogeneous cancer.  Variant calling was performed by GATK, FamSeq and 
CASAVA to detect single nucleotide variations (SNVs), insertions/deletions (indels) 
and structural variants. Shared variants within each family were identified and 
prioritized based on expression in fetal kidney, minor allele frequency less than 1%, 
and the predicted functional significance of the alteration on protein structure.  
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Candidate mutations were then assessed in each family for cosegregation with the 
affected/obligate carrier status.  To examine the sequence integrity and frequency of 
candidate gene mutations in Wilms tumor, a comprehensive mutation analysis of each 
candidate gene, including Sanger sequencing of the entire coding region and 
quantitative PCR (qPCR) to detect exonic insertions/deletions, was performed using 
genomic DNA from 47 additional Wilms tumor families and tumor DNA from 175 
sporadic Wilms tumors.  As a result, a recurrent 570kb germline duplication including 
NBAS, DDX1, MYCN and MYCNOS was identified in 4% of families, as well as 
germline missense mutations in DICER1 (4% of families) and SPHK2.  Functional 
studies demonstrate that the missense mutation identified in SPHK2 does not have an 
effect on apoptosis or proliferation, but instead alters SPHK2 subcellular localization 
and expression of target genes.  
Our analysis resulted in the successful identification of Wilms tumor 
predisposition genes in each family, and provided support for the involvement of 
DICER1 and DDX1/MYCN in Wilms tumor development. Additionally, our 
identification of SPHK2 as the 19q familial Wilms tumor predisposition gene has 
opened up new avenues of research into the role of sphingolipid signaling in 
nephrogenesis and cancer development. Significantly, the communication of these 
results directly to patients within each family allows for the continued monitoring of 
new family members for the potential early detection of not only Wilms tumor, but 
other phenotypes associated with the specific gene mutations.  
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Chapter 1. INTRODUCTION 
1.1. Understanding Wilms tumor biology 
Wilms tumor is an embryonal renal malignancy that is predominately 
diagnosed in children before 10 years of age.1 It is the most common pediatric kidney 
cancer, occurring in 1 in 10,000 live births in North America. Unilateral cases 
represent 90-95% of Wilms tumor diagnoses and have a mean age of diagnosis 
occurring around 43 months. Bilateral cases are usually diagnosed at 33-38 months.1 
It was this kidney malignancy, in addition to neuroblastoma and retinoblastoma, which 
constituted the three tumor types studied in the establishment of the “two-hit” model of 
tumor suppression.2 Although the survival rate for Wilms tumor is over 90% for 
confined disease, the development of secondary malignancies due to current therapy 
is common. Thus, identification of the genes and molecular pathways driving Wilms 
tumorigenesis is critical for 1) our understanding of the biology of Wilms tumor and 
other embryonal tumors, and 2) the development of targeted therapies aimed at 
reducing cancer mortality, while concurrently eliminating harmful side effects.  
Wilms tumor is thought to originate from pluripotent embryonic renal progenitor 
cells that are unable to differentiate normally. Although the majority arise sporadically, 
roughly 2% of patients have a family history of Wilms tumor. In these instances, an 
earlier age of diagnosis and increased prevalence of bilateral tumors is typically 
observed, although this varies between families.1-4 Until recently, the genetic etiology 
of most cases of non-syndromic Wilms tumor has remained a mystery, as traditional 
candidate gene approaches have been inefficient in revealing causal elements of this 
genetically heterogeneous cancer. High-throughput next-generation sequencing has 
represented a turning point in the identification of disease genes with the ability to 
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screen large numbers of genes simultaneously in an unbiased manner. Using this 
technology, surveying the genetic landscape of Wilms tumor has just begun to unravel 
the mutation events responsible for both sporadic and familial cases. However, the 
identification of “Wilms tumor genes” is far from complete. While the genes 
responsible for sporadic Wilms tumor cases are known in approximately 50% of 
cases, the cause of the majority of familial Wilms tumor cases is largely unknown. 
 
1.1.1. Kidney Development 
Wilms tumors originate from undifferentiated renal mesenchyme and represent 
an example of aberrant kidney development resulting in cancer. Kidney development 
commences at approximately day E36 in humans (E10.5 in mice), and is the result of 
complex reciprocal interactions between two tissues derived from the intermediate 
mesoderm: the metanephric mesenchyme, which differentiates into stromal cells and 
epithelial components of the nephron, and the ureteric bud, which gives rise to the 
collecting duct system.5-6 Signals produced from the metanephric mesenchyme 
induce the ureteric bud to bifurcate as it invades the mesenchyme, resulting in the 
induction of mesenchyme condensation along the surface of the bud (Figure 1). A 
portion of the condensed mesenchyme forms pretubular aggregates adjacent and 
interior to the tips of the branching ureteric bud. These pretubular aggregates then 
undergo a mesenchymal-to-epithelial transition to form the epithelia (comma- and S-
shaped bodies), which later develop into the nephron.6 The stromal elements, derived 
from cells of the metanephric mesenchyme that were not induced to condense and 
epithelialize, develop in the periphery of the mesenchyme and between the branches  
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Figure 1. Kidney development. Interactions between the metanephric mesenchyme 
(MM) and ureteric bud (UB) result in invasion of the UB into the MM, leading to 
mesenchyme condensation and formation of pretubular aggregates. These pretubular 
aggregates go on to form the epithelial components (renal vesicle, comma-shaped 
bodies, S-shaped bodies) of the kidney. The distal end of the S-shaped body 
connects to the ureteric bud, while the proximal end joins to form the glomerulus.  
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of the ureteric bud. These stromal cells include pericytes and mesangial cells. The 
iterative branching of the ureteric bud yields the collecting duct system of the kidney. 
This entire process kidney development is completed by week 34 in humans, and 
postnatal day 7 in mice. 
 
1.1.2. Wilms tumor resembles early kidney organogenesis 
The distinctive histology of Wilms tumors is reminiscent of fetal kidney 
development and suggests that Wilms tumor arises from pluripotent embryonic renal 
progenitors that, instead of undergoing normal differentiation to form the functional 
kidney, show arrested differentiation and aberrant proliferation, ultimately resulting in 
a Wilms tumor. This is supported by a number of morphological and molecular 
observations. First, the characteristic triphasic appearance of Wilms tumor is 
histologically comparable to that of the developing kidney (Figure 2). Wilms tumors 
frequently contain variable proportions of three cellular components derived from the 
fetal mesenchyme: epithelial, blastemal, and stromal elements.8 The epithelial 
elements resemble comma-shaped bodies, S-shaped bodies and glomeruli. The 
blastemal component is comprised of small, densely packed cells representing 
metanephric mesenchyme, while the stromal elements resemble fibroblasts, skeletal 
muscle or neural elements. Moreover, gene expression studies provide further 
support for a developmental-origin of Wilms tumors in that genes expressed during 
early kidney development (PAX2, HOXA11, SIX1, EYA1, SALL2, MEOX1) have a 
tendency to be overexpressed in Wilms tumors, while genes expressed at later stages 
of nephrogenesis are downregulated in Wilms tumors.9 Additionally, genome-wide 
chromatin profiling of Wilms tumors, embryonic stem cells, and normal kidney tissue 
!! 5!!
 
 
 
 
 
 
 
  Embryonic Kidney    Wilms tumor 
 
Figure 2. Wilms tumor histology. Wilms tumors (right) are histologically similar to the 
embryonic kidney (left). The triphasic histology of Wilms tumors shows blastemal, 
epithelial, and stromal components reminiscent of fetal kidney development. However, 
the tumors lack correct formation of glomeruli and nephrons. 
 
 
 
 
 
 
 
!! 6!!
indicates that Wilms tumors share an epigenetic landscape with renal stem cells, with 
increased domains of histone H3 lysine 4 trimethylation (K4me3) suggestive of an 
open chromatin environment.10 Taken together, the histological morphology, gene 
expression and chromatin profiling data imply that Wilms tumors arise from a subset 
of cells arrested at an early metanephric mesenchymal stage during nephrogenesis. 
Consistent with this hypothesized ontogeny, genes mutated in Wilms tumors include 
those involved in directing the differentiation of early metanephric mesenchymal cells, 
as well as components of signaling pathways critical for kidney morphogenesis.11 
 
1.1.3. Nephrogenic Rests: the connection between nephrogenesis and 
nephroblastoma 
Wilms tumors are thought to arise from nephrogenic rests, which are benign 
foci of undifferentiated fetal mesenchyme that, instead of fully differentiating into renal 
parenchyma by 36 weeks of gestation, persists after renal embryonic development is 
complete. These nephrogenic rests are found in the kidneys of 1% of infants, 30-40% 
of sporadic Wilms tumor cases, and 100% of bilateral cases.12 Noninvasive follow-up 
of these precursor lesions have shown they have the ability to progress, sclerose, or 
regress. Two types of nephrogenic rests have been described based on their location 
within the kidney. Intralobar nephrogenic rests (ILNR) are situated centrally within the 
renal lobe, represent approximately 10% of nephrogenic rests, and are associated 
with mutations or deletions in WT1. In contrast, perilobar nephrogenic rests (PLNR) 
are located at the periphery of the renal lobe and represent 90% of nephrogenic rests. 
Nephrogenic rests often share the same genetic defects found in Wilms tumors. 
These shared mutations are not present in the surrounding normal kidney tissue, 
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suggesting that they are responsible for the formation of Wilms tumor precursor 
lesions in the kidney. Additional mutations only in the tumor tissue indicates that 
neoplastic transformation of nephrogenic rests results in the development of Wilms 
tumor.13-14 
 
1.2. The genetics and emergence of new genes in Wilms tumor 
The etiology of Wilms tumor is heterogeneous with multiple genes known to 
result in Wilms tumor formation. These genes and loci, identified through molecular 
and cytogenetic analyses, have been found mutated primarily in sporadic Wilms 
tumors (Table 1) and includes somatic mutations in WT1, CTNNB1, WTX, TP53, 
MYCN, SIX1/2, miRNA pathway genes, and epigenetic abnormalities at 11p15.15-18 
Wilms tumor is a relatively euploid cancer and, like other pediatric malignancies, the 
number of somatic mutations found in tumors is low.16 This suggests that these 
somatic alterations acquired by tumor cells are significant events in the initiation of 
Wilms tumor.  
 
 
 
 
 
 
 
 
 
!! 8!!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene   Effect of mutation   Somatic or Germline? 
WT1   Inactivation of protein   Both 
WTX   Inactivation of protein   Somatic 
TP53   Inactivation of protein   Both 
IGF2   Biallelic expression    Both 
CTNNB1  Activating     Somatic 
CTR9   Inactivation of protein   Germline 
DROSHA  Alteration of miRNA biogenesis  Somatic 
DGCR8  Alteration of miRNA biogenesis  Somatic 
MYCN  Activating     Both 
SIX1   Activating     Somatic 
SIX2   Activating     Somatic 
 
 
Table 1. Genes involved in Wilms tumor development. 
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1.2.1. WT1 and CTNNB1 
Wilms tumor protein 1 (WT1) was the first gene implicated in Wilms tumor 
development and initially provided most of our understanding of the relationship 
between kidney development and tumorigenesis. WT1, a zinc-finger transcription 
factor, is essential for renal development and plays a critical role in the regulation of 
expression of genes involved in nephrogenesis.19 Moreover, WT1 directs the 
mesenchymal to epithelial transition of the metanephric mesenchyme through 
upregulation of WNT4, leading to the differentiation of blastemal cells into mature 
nephrons.20  Mutations in WT1 have been identified in approximately 20% of sporadic 
Wilms tumors, and result in inactivation of the protein.15 
The WNT pathway is critical for proper kidney development. Therefore, it is not 
surprising that components of this signaling pathway, such as CTNBB1, have been 
found to be mutated in Wilms tumors.21 Interestingly, there is a strong association 
between WT1 and CTNNB1 mutations, as the majority of WT1-mutant tumors harbor 
activating mutations in CTNNB1.15,22 These mutations result in stabilization of beta-
catenin and translocation to the nucleus where it activates downstream targets.21  
 
1.2.2. WTX 
WTX, also known as family with sequence similarity 123B (FAM123B) is 
mutated in roughly 20% of sporadic tumors. Approximately 2/3 of these tumors harbor 
deletions of the entire WTX gene, while the others carry missense alterations, or 
nonsense and frameshift mutations resulting in a truncated protein.15,23-25  WTX acts 
as a negative regulator of CTNNB1 by interacting with the beta-catenin destruction 
complex in the cytoplasm to promote beta-catenin ubiquitylation and degradation.26 
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Truncating WTX mutations identified in Wilms tumors result in the deletion of the beta-
catenin-binding region. As a result, beta-catenin is stabilized, accumulates in the 
nucleus, and activates downstream target genes. Germline mutations in WTX, 
underlying osteopathia striata with cranial sclerosis (OSCS), do not predispose to 
Wilms tumors, however most children with OSCS die at an early age.27 
 
1.2.3. TP53 
TP53 is of particular importance because, although it is only mutated in a 5% of 
sporadic tumors, its mutation is associated with relapse and poor prognosis due to 
metastasis and resistance to therapy.28-29 The presence of anaplasia defines Wilms 
tumors that have unfavorable histology and poor prognosis, and somatic TP53 
mutations have been identified in ~75% of anaplastic Wilms tumors.30-31 The 
mutations occur at hotspot residues or lead to truncated protein.32 
 
1.2.4. MYCN 
Approximately 10% of Wilms tumors show low-level MYCN amplification, with 
no preference for histological subtypes.33-37 The increased copy number is typically 
modest when compared to other tumor types which also show MYCN amplification, 
such as neuroblastoma. MYCN amplification usually includes other flanking genes as 
well due to their close proximity, most often DDX1, which is telomeric to MYCN. 
Recurrent somatic point mutations in MYCN affecting codon 44 of the Aurora A kinase 
interaction domain have recently been identified in tumors, although the significance 
of these mutations is not known.16-17 It has been suggested that this recurrent 
mutation has an activating function. MYCN is a transcription factor that controls 
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expression of genes involved in proliferation and differentiation, and is critical for brain 
development and essential for kidney morphogenesis.38 
 
1.2.5. SIX1/2 mutations 
Two recent studies used exome sequencing of blastemal and favorable 
histology Wilms tumors to identify somatic mutations contributing to the development 
of Wilms tumors. These analyses revealed a recurrent somatic hotspot mutation in 
exon 1 (Q177R) of SIX1 in 10% and 7% of cases, respectively.17,32 Chromatin 
immunoprecipitation sequencing (ChIP-seq) and global gene expression analysis 
indicated this mutation results in the alteration of both DNA binding specificity and 
subsequent gene expression profiles of downstream target genes. Additionally, the 
equivalent Q177R mutation in SIX2 was also identified as a somatic change in  Wilms 
tumors. Expression analysis of SIX1/2-mutant tumors showed an upregulation of cell-
cycle and kidney developmental genes, suggestive of a renal progenitor cell state.32  
 
1.2.6. Epigenetic alterations at 11p15 
Epigenetic alterations at 11p15 are the most common alteration in Wilms tumor 
cases. These defects are usually isolated, non-heritable events and typically are only 
seen in sporadic cases, although not many familial tumors have been studied to date. 
Loss of imprinting (LOI) or loss of heterozygosity (LOH) at 11p15 is found in most 
tumors.39 A cluster of imprinted genes is located at this location. This cluster includes 
IGF2, which is an embryonic growth factor, and H19, which expresses a noncoding 
RNA. The H19 imprinting control region is located at 11p15 that controls expression of 
IGF2 and H19.  This region is differentially methylated depending on the chromosome 
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parent of origin. Methylation of the maternal allele prevents CTCF binding and IGF2 
expression, while H19 is actively expressed. Conversely, hypomethylation of the 
paternal chromosome allows CTCF to bind, permitting IGF2 expression while blocking 
H19 expression. In Wilms tumors, loss of the maternal allele and duplication of the 
paternal allele by either LOH or aberrant gain of methylation at the H19-ICR results in 
biallelic IGF2 expression. Biallelic IGF2 expression alone is not sufficient for Wilms 
tumor development, as LOH of 11p15 was identified in the normal kidney and blood 
cells of WT patients. 40 
 
1.2.7. MicroRNA Pathway Genes 
 The most recent genes implicated in Wilms tumor development are those of 
the miRNA biogenesis pathway. This pathway produces mature miRNAs that 
negatively regulate the expression of target proteins by targeting their mRNA 
transcripts. This pathway was first connected to Wilms tumor formation when 
inactivating mutations in DIS3L2 were identified in Perlman syndrome.41 DIS3L2 
specifically targets uridylated pre-let-7 miRNAs for degradation, and a small fraction of 
patients with DIS3L2 mutations are predisposed to Wilms tumor development. 
Additionally, studies have demonstrated the importance of specific miRNAs in kidney 
development.42  
A number of recent studies have also identified mutations in DGCR8, 
DROSHA, XPO5, TARBP2 and DICER1 in Wilms tumors.16-17,32 Somatic 
heterozygous mutations in DROSHA, the most commonly mutated miRNA pathway 
gene, were identified in ~12% of Wilms tumors. These were recurrent E1147K 
mutations disrupting the Mg2+ binding site of the RNase IIIb domain. MicroRNA 
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expression profiling demonstrated loss of the miR-200 family, whose members 
include those involved in the mesenchymal-to-epithelial transition, consistent with the 
pathology of the tumors. Germline and somatic mutations in DICER1 have been 
identified less frequently in Wilms tumors, but appear to contribute to Wilms tumor 
development through altering the balance of 5p/3p miRNAs (described in chapter 3). 
 
1.3. Familial Predisposition to Wilms tumor 
The genes responsible for sporadic Wilms tumor cases are known in 
approximately 50% of cases. However, these genes rarely contribute to instances of 
familial Wilms tumor. Approximately 2% of Wilms tumor patients have an affected 
relative, usually a sibling or cousin. These cases typically present at an earlier age 
than sporadic Wilms tumor presumably due to the inheritance of a germline mutation 
predisposing to cancer development. The majority of Wilms tumor families are small, 
often containing 2-3 affected individuals. Among these affected individuals, males and 
females are equally represented. Evidence suggests that the predisposition gene is 
not subjected to imprinting effects, as there is no gender bias in the obligate carrier 
parents of affected children. Familial Wilms tumor is also observed in a range of 
ethnicities.  Although most familial Wilms tumor cases are non-syndromic, there are a 
minority of familial cases associated with Beckwith-Wiedeman syndrome, Denys-
Drash syndrome, WAGR syndrome, Perlman syndrome, and rarely, in DICER1 
Syndrome.   
Familial WT predisposition displays an autosomal dominant inheritance pattern 
with incomplete penetrance estimated at 30%.2,43-44 Familial predisposition genes 
have been localized by genetic linkage analysis to 17q12-21 (FWT1) and 19q13.3 
(FWT2), although neither has been identified.45-46  The lack of linkage of some WT 
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families to these regions indicates additional familial WT genes exist.47 This genetic 
heterogeneity could be the reason for variation seen in families with respect to  
penetrance, frequency of bilateral disease, and age of diagnosis. For example, 
although familial Wilms tumor is typically diagnosed 12 months earlier than sporadic 
cases, Wilms tumors occurring in 17q-linked families are diagnosed at a median age 
of 6 years. On the other hand, families linked to chr19q show variable ages of 
diagnosis, ranging from 14 to 204 months.  
 
1.3.1. Previous Identification of familial WT predisposition Genes 
With advancements in next-generation sequencing technologies, the 
mutational landscape of Wilms tumor is becoming more clear. The overwhelming 
majority of these studies, however, focused on sporadic Wilms tumors. Nonetheless, 
both traditional and high-throughput sequencing efforts have contributed to a small list 
of genes that, when mutated, are associated with predisposition to familial Wilms 
tumor. These genes include WT1 (rarely), CTR9, DICER1, and copy number 
alterations including MYCN and DDX1. 
Germline mutations in WT1 are known to predispose to Wilms tumor, however 
most germline WT1 mutations are frequently de novo. There are rare cases in which 
germline WT1 mutations inherited from an affected or obligate carrier parent results in 
familial Wilms tumor. These mutations have been reported in very few families, most 
of which are small.48-51 In general, familial Wilms tumor cases are not due to germline 
mutations in WT1. 
Recently, next-generation sequencing technology allowed for the identification 
of CTR9 as a Wilms tumor susceptibility gene. In this study, inactivating mutations in 
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CTR9 were identified in 3/35 Wilms tumor families.52 CTR9 is a gene involved in RNA 
Polymerase elongation by association with the PAF1 complex. Mutations in additional 
members of this complex have been identified in Wilms tumor cases, providing 
additional support for CTR9 as a cancer predisposition gene. Although CTR9 is a 
newly established Wilms tumor predisposition gene, it should be noted that these 
mutations were found in a fraction of familial Wilms tumor cases, which illustrates the 
characteristic genetic heterogeneity of Wilms tumor predisposition. 
The research described in this Thesis served to expand the genetic etiology of 
Wilms tumor occurring in families, and successfully resulted in the identification of the 
predisposing alterations in three families whose whole genomes were sequenced. We 
identified germline mutations in DICER1, which have recently been found in six 
families with DICER1 Syndrome-associated Wilms tumors (described in chapter 3). 
Additionally, copy number alterations at chr2p24, encompassing the MYCN locus, 
have recently been identified in a family with a history of nephroblastomatosis and 
Wilms tumor. Our analysis resulted in the identification of two Wilms tumor families 
harboring copy number alterations of this region (chapter 4). Finally, our identification 
of SPHK2 as a candidate Wilms tumor predisposition gene on chr19q (chapter 2) 
opens new avenues of research into the role of chromatin regulation and lipid 
signaling in Wilms tumor initiation. 
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1.4. Significance 
    The study of Wilms tumor has generated many concepts that are fundamental 
to our understanding of the genetic etiology of cancer. The first "Wilms tumor gene" 
identified, WT1, plays an important role in the development of multiple organ systems 
and alterations of the gene or its expression are involved in many tumor types. 
Interestingly, while WT1 was originally isolated by virtue of being a "Wilms tumor 
gene", it is now recognized that WT1 plays an important, although not well 
understood, role in a variety of cancers, including acute lymphocytic leukemia (ALL). 
Additionally, a WT1 vaccine has shown therapeutic promise against AML, 
glioblastoma, breast and lung carcinoma in Phase I/II clinical trials. Thus it is very 
plausible that the identification -- and the understanding of the aberrant function of -- 
other "Wilms tumor genes" not only will represent a major step in our understanding of 
cancer predisposition, but will also greatly accelerate work in the area of cancer 
genetics in general and will potentially identify therapeutic targets for very common 
cancers.  
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Chapter 2: Whole genome sequencing to identify candidate Wilms 
tumor predisposition genes 
 
2.1. Introduction 
A number of high-throughput, massively parallel sequencing (next-generation 
sequencing) platforms developed since the completion of the human genome project 
has allowed for the generation of unprecedented amounts of data compared to 
sequencing by capillary electrophoresis. Not only is this technology more cost 
effective per base than traditional sequencing methods, but large amounts of data can 
now be generated in a fraction of the time compared to conventional sequencing 
approaches. Recent successes in disease gene identification using next-generation 
sequencing technology has demonstrated the power of whole exome- and genome 
sequencing studies to understand drivers of human disease and cancer. Fortunately, 
the rapid evolution of bioinformatics analysis programs combined with the falling cost 
of whole genome sequencing has allowed us to employ this technology to pinpoint 
candidate genes predisposing to familial Wilms tumor.  
 
2.2. Illumina Whole Genome Sequencing 
The Illumina sequencing platform is one of the most widely adopted next-
generation sequencers used by both research and clinical laboratories due to its low 
error rates and cost efficiency. The sequencing process begins with library 
preparation, in which genomic DNA is randomly fragmented followed by the ligation of 
adapters to the ends of each fragment. The adapters facilitate the hybridization to an 
Illumina flow cell which contains surface-bound oligos complementary to the adapter 
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sequences. Here, solid-phase amplification of each single template creates clusters of 
identical copies of the fragment to generate a sufficient signal for the detection of 
incorporated bases. Illumina’s sequencing by synthesis approach uses a reversible 
terminator method to distinguish single fluorescently-labeled deoxynucleoside 
triphosphates (dNTPs) as they are incorporated into growing DNA strands. Following 
the addition of a single labeled dNTP into the growing nucleic acid chain, an image is 
taken to identify the incorporated base. The labeled base is then cleaved for the next 
base incorporation event to take place. The nucleotide calls are distinguished from 
one another based on the signal intensity measurement, resulting in the sequence of 
bases from the fragment.  
  
2.3. Whole genome sequencing in three Wilms tumor families  
To identify Wilms tumor predisposition genes, we sequenced the whole 
genome of eleven individuals from three Wilms tumor families using the Illumina 
sequencing platform. The individuals from each family were chosen for whole genome 
sequencing based on being: 1) affected individuals or individuals known to be an 
obligate carriers of the predisposing mutation by virtue of having an affected child, 2) 
distantly related (to reduce the number of shared variants for further investigation), 
and 3) on our already having a DNA sample from them. Informed consent was 
obtained from all study participants, and approval for this research was obtained from 
the Institutional Review Board at MD Anderson Cancer Center.  
Illumina paired-end libraries were constructed from genomic DNA by the MD 
Anderson Cancer Center Sequencing Core Facility. The advantage of paired-end 
libraries is that, in addition to high quality sequence information, they also provide 
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long-range positional information allowing for the highly precise alignment 
of sequence reads. Libraries were sequenced at approximately 30X coverage using 
the Illumina HiSeq 2000 system, which is sufficient coverage to allow for the detection 
of germline sequence variants. The resulting sequence data was then contained in 
fastq files for processing, alignment and variant calling. 
 
2.4. Bioinformatic analysis 
While the ability to generate larger amounts of data through next-generation 
sequencing has improved exponentially, the continued development of faster, more 
accurate bioinformatic analysis programs has not kept pace, resulting in a bottleneck 
at the analysis stage. Additionally, there are challenges associated with identifying 
rare variants to better understand the genetic basis of human diseases. Identification 
of variants depends on many factors. Considerations such as coverage depth and 
base quality scores have an impact on determining if an alteration is called or not, as 
well as the parameters which set the threshold for variant calling. Recognizing this, 
we established a collaboration with Wenyi Wang, PhD at MD Anderson, who 
developed FamSeq, a computational tool that performs family-based variant calling in 
next-generation sequence data. Of the eleven individuals sequenced in our study, 
three individuals comprised a trio of affected parent/child and unaffected parent. 
Using this family-based sequencing approach, we used information from the trio to 
more accurately identify germline mutations by calculating the probability of variants 
given the entire family’s raw sequence measurements. Fortunately, the data 
generated from this work has not only served to advance our understanding of Wilms 
tumor genetics, but also to advance a computational tool aimed at improving the 
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identification of rare variants in family sequencing studies. 
2.4.1. Read alignment and variant calling 
100bp paired-end sequence reads that passed instrument QC from each 
individual were processed and aligned to the GRCh37/hg19 human reference 
genome using the Burrows-Wheeler Aligner (BWA) v0.5.9. PCR duplicates were 
marked by Picard v1.46. Variant calls were produced using the Genome Analysis 
Toolkit (GATK), FamSeq, and CASAVA, resulting in data sets which include single 
nucleotide polymorphism (SNP) calls, insertions, and deletions with respect to the 
reference sequence, as well as confidence scores for every covered position in the 
genome. To identify copy number variation, the total number of read counts for each 
position across the whole genome was extracted from the bam file. The mean read 
counts for a fixed window of 50 bases was calculated and used as input for a Hidden 
Markov Model (HMM) segmentation algorithm. This produced copy number segments 
assigned to gains or losses depending on the ratio of total median read counts within 
each segment to the mean sequencing depth across the entire genome. 
2.4.2. Identification and annotation of intra-family shared variants  
Using the variant calls generated by GATK, FamSeq and CASAVA, we first 
compared the genotypes between the affected/obligate carrier individuals in the same 
family to identify variants that are shared. These variant were contained in variant call 
format (vcf) files for each individual. This analysis generated three lists of variants 
specific to the three families in our study. In each family, this approach reduced the 
list of putative risk alleles to those which are 1) less likely to be artifacts, and b) 
presumably inherited from the same (carrier) relative. Using this approach, our 
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strategy of sequencing the most distantly related affected family members and 
identification of overlapping variants reduced the list of candidate variants because 
the more distantly they are related, the fewer genetic variants they shared. Variants 
that were not shared between family members were discarded from further 
investigation, as the criteria for the predisposition gene includes the presence of the 
variant within all affected/obligate carrier individuals.  
Once shared variants were identified, ANNOVAR 
(http://www.openbioinformatics.org/annovar) was used to aid in the investigation of 
the functional significance of variants by annotating each variant with respect to 
location within the genome (intergenic, intronic, exonic, or regulatory regions) using 
the annotate_variation.pl –geneanno –buildver hg19 command. Variants present in 
dbSNP137 were identified using the annotate_variation.pl –dbtype snp137 command. 
Variant frequencies from the 1000 Genomes database were also obtained using 
ANNOVAR. Alterations were also examined for their presence in the NHLBI Exome 
Variant Server (https://esp.gs.washington.edu/drupal). 
 Variants in exonic regions which could potentially affect protein structure 
(nonsynonymous and frameshift variants) were identified and further annotated using 
ANNOVAR to obtain the following scores: SIFT (annotate_variation.pl avsift), 
PolyPhen (annotate_variation.pl ljb_pp2), MutationTaster (annotate_variation.pl 
ljb_mt), and PhyloP (annotate_variation.pl ljb_phylop). This produced a list of variants 
with predictions as to whether they are deleterious, as well as conservation scores to 
assess whether identified variants occur within evolutionarily conserved regions which 
could include promoter regions and sequences important for RNA expression, RNA 
stability, and RNA translation. 
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2.4.3. Filtering and prioritization of variants 
One advantage of whole genome sequencing technology over first-generation 
methods, such as Sanger sequencing, is the generation of large amounts of data with 
variant calls across the entire genome. This typically results in >4 million variant calls 
for each whole genome. In this current study, with whole genome sequence data from 
eleven individuals, the amount of data generated required the application of a discrete 
set of filters to prioritize those variants which are most likely to be the cause of 
disease in the families. As previously described, we first identified intra-family shared 
variants because potential Wilms tumor predisposing mutations will be those that are 
present in all affected/obligate carrier individuals in a family, and absent in unaffected 
family members. We then filtered these shared variants using dbSNP137 and the 
1000 Genomes databases to remove variants with a minor allele frequency (MAF) 
greater than 1% in those databases. This reduced a large list of potential candidate 
genes by removing all variants that are commonly occurring in the general population, 
with the rationale being familial Wilms tumor represents a small proportion of all 
Wilms tumor cases and Wilms tumor is relatively rare in the population. Consequently, 
we expected risk alleles to occur at a low frequency in the general population or to 
even be novel variants. As such, variants with a MAF greater than 1% and present in 
these databases were excluded from our initial analysis. Although we prioritized 
variants based on their presence in dbSNP, it is important to note that pathogenic 
variants have previously been included in dbSNP. With this in mind, our initial analysis 
included only those variants not present in dbSNP, although the comprehensive list of 
variants was archived for future examination should we be unsuccessful in identifying 
a promising candidate variant. 
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In order to identify the familial Wilms tumor predisposition mutation in each 
family, the variants were then screened by function and embryonic expression 
pattern. Similar approaches taken by other studies have proven effective in filtering 
out non-causal mutations. Previous studies have shown that most alleles that are 
known to underlie Mendelian disorders disrupt protein-coding sequences. Therefore, 
mutations of high interest (“first tier variants”) included those that have an effect on 
protein via non-synonymous mutations, insertions or deletions in a coding region. 
“Second tier” variants included those that occur outside the coding region of genes 
(intronic, intergenic regions). These second tier variants were saved for future 
evaluation in the case that promising first tier variants were not identified. In addition, 
higher priority was assigned to genes expressed in fetal kidney, as Wilms tumor is a 
cancer involving fetal renal development.  
The resulting data was initially assessed for variants that occurred in more than 
one of the three families or that affected the same gene/functional element in more 
than one family. However, this analysis failed to identify variants in the same gene 
from all three families. We next shifted our analysis to variants from each individual 
family (described in more detail in chapters 3-5). Following the identification of 
candidate predisposition genes, the application of a co-segregation analysis was used 
to further prioritize the set of key functional variants. This was because familial Wilms 
tumor is rare among Wilms tumor cases, and the chance that both parents of an 
affected familial Wilms tumor patient carry the predisposing mutation is unlikely. The 
results from this analysis are described in the following three chapters. 
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CHAPTER 3: Identification of sphingosine kinase 2 (SPHK2) as a 
putative 19q familial Wilms tumor predisposition gene. 
 
3.1. INTRODUCTION 
Following a genetic linkage analysis of a large multigenerational WT family, a 
3.4Mb region of chr19q13 was identified as the location of a gene which predisposes 
to familial Wilms tumor.46 Traditional approaches (i.e. Sanger sequencing) to isolate 
the causal 19q familial Wilms tumor are not practical due to the number of genes 
(~137) within the linked region. Fortunately, advancements in next-generation 
sequencing technologies have allowed for the cost-efficient, high throughput 
sequencing of individuals within the family to identify the predisposition alteration. 
Using whole genome sequencing, the entire genetic landscape of six individuals 
within the family was surveyed to pinpoint the predisposing alteration in the family. 
This resulted in the identification of sphingosine kinase 2 (SPHK2), an enzyme 
involved in the production of sphingosine 1-phosphate, as a putative 19q familial 
Wilms tumor predisposition gene. 
 
3.1.1. S1P signaling 
Sphingosine 1-phosphate (S1P), a bioactive phospholipid, has emerged as an 
important regulator of many fundamental cellular processes.53 In particular, S1P has 
received considerable attention due to its discovery as an important extra- and 
intracellular signaling molecule, serving as the mechanism whereby S1P regulates 
cell proliferation, survival, differentiation, migration and inflammation. Invariably, with 
diverse roles in such cellular activities, disruptions of S1P signaling have been 
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implicated in the development and progression of cancer, and progress is being made 
to therapeutically target the biosynthesis of S1P by targeting the enzymes involved in 
the synthesis of S1P: the sphingosine kinases (SPHK1 and SPHK2).54.55 
S1P is derived through a process of sphingolipid synthesis and degradation 
pathways (Figure 3). At the center of this network is ceramide which is deacylated to 
form sphingosine, the precursor to S1P. After phosphorylation of sphingosine by 
either SPHK1 or SPHK2, S1P is either exported from the cell or interacts with 
intracellular targets to elicit a number of effects. S1P can be exported out of the cell 
by members of the ABC transporter family where it acts extracellularly by binding to a 
family of five G-protein couple receptors, S1PR1-5. This results in autocrine or 
paracrine signalling through the receptors, which are coupled to various G proteins. 
Differential expression of the various S1P receptors mediates the cellular response 
through the ERK, Rac and Rho, and PI3K/AKT pathways. S1P can be 
dephosphorylated or degraded by S1P lyase to form hexadecenal and 
phosphoethanolamine.  
Current dogma suggests the levels of ceramide, sphingosine and S1P forms a 
“lipid rheostat”, whereby the regulation of synthesis and catabolism of these 
sphingolipids controls cell fate. Data from cell culture experiments shows that 
ceramide and sphingosine are pro-apoptotic and when their levels exceed that of 
S1P, the cell is directed towards apoptosis. Ceramide directly activates a number of 
targets that mediate its pro-apoptotic functions, including protein phosphatases 1, 2A 
and 2C, whereas sphingosine binds and initiates the inactivation of the pro-survival 
protein 14-3-3.102-105 Conversely, S1P is anti-apoptotic and results in cellular 
proliferation, migration and survival when its production surpasses ceramide and 
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sphingosine levels. This is accomplished by modulation of extracellular-signal-
regulated kinases 1/2 (ERK1/2), Rac and Rho, the phosphoinositides 3-kinase 
(PI3K)/AKT pathway and phospholipase C (PLC).105-106 These effects also display 
cell- or tissue-specific variability resulting from the differential expression of S1P 
receptors and the various G proteins they couple to.107 Thus a delicate balance in the 
levels of these lipids has the potential to direct cells toward a pro-survival or pro-
apoptotic outcome. 
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Figure 3. Sphingolipid Metabolism. The sphingosine kinases (SPHK1 and SPHK2) 
phosphorylate their substrate, sphingosine, producing the bioactive lipid, sphingosine 
1-phosphate (S1P). The reverse reaction is catalyzed by S1P phosphatase. S1P can 
be irreversibly degraded to produce ethanolamine phosphate and trans-2-
hexadecenal. The entire sphingolipid metabolic pathway comprises the “sphingolipid 
rheostat” whereby the levels of each lipid dictates cell fate. Higher levels of ceramide 
and sphingosine, relative to S1P, induces cellular apoptosis. Conversely, when S1P 
levels increase above ceramide and sphingosine, the cell is directed to proliferate. 
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3.1.2. Sphingosine kinase 2 (SPHK2) 
There are two mammalian sphingosine kinases, SPHK1 and SPHK2, which are 
located on chromosome 17q25 and chromosome 19q13, respectively.56-57 These 
kinases share 80% similarity and 45% overall sequence identity. Both SPHKs contain 
five highly conserved regions which contain ATP binding and catalysis regions (Figure 
4).  While both catalyze the phosphorylation of sphingosine, SPHK2 contains 
additional residues at its N-terminus and central region that are not present in SPHK1, 
suggesting that SPHK2 has additional functions.58 Opposing roles of the enzymes 
have also been suggested due to the presence of both a nuclear localization 
sequence (NLS) and a nuclear export sequence (NES) in SPHK2 that allows shuttling 
between the cytoplasm and nucleus.59-60 These sequences are not found in SPHK1. 
Additionally, differences in sphingosine kinase expression during embryonic 
development suggests SPHK1 and SPHK2 perform separate responsibilities. 
Two forms of SPHK2 have been described. The longer isoform (SPHK2-L) has 
an additional 36 amino acids at the N-terminus compared to the short isoform (SPHK-
S).61 Although there is much less sequence conservation in vertebrates in the region 
encoding these 36 amino acids compared to the rest of the protein (UCSC Genome 
Browser), the SPHK2-L appears to be the predominant form in most human tissues -- 
with the notable exception of the brain and kidney.61 Consistent with this, we have 
observed a preponderance of SPHK2-S in human fetal kidney by real-time RT-PCR. 
Human and mouse SPHK2-S are highly homologous, with 83% identity and 90% 
similarity. Notably, SPHK2-S is the only isoform expressed in the mouse. 
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Figure 4. Comparison of SPHK1 and SPHK2. Each kinase contains five conserved 
domains. An ATP binding site resides within C2 of each enzyme.  SPHK1 (384 amino 
acids) and SPHK2 (SPHK2-long: 654 amino acids, SPHK2-short: 618 amino acids) 
share 80% similarity and 45% overall sequence identity.  Also shown are the SPHK2 
long isoform (SPHK2-long) and SPHK2 short isoform (SPHK2-short). These two 
SPHK2 isoforms differ by 36 amino acids present at the N-terminus of SPHK2-long.  
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SPHK2 possesses an intrinsic catalytic activity which can be enhanced by 
growth factors such as EGF.62 This is mediated by ERK1-dependent phosphorylation 
at Ser-351 and Thr-578, resulting in a 2-fold increase in catalytic activity.63  
Mutagenesis experiments have shown that mutating G212 interferes with ATP binding 
and abolishes SPHK2 catalytic activity. Genetic knockout of SPHK1 or SPHK2 in mice 
results in no obvious phenotypic abnormalities suggestive of a compensatory 
mechanism, while double knockout of both SPHKs is embryonic lethal around E11.5 
due to defects in neurogenesis and angiogenesis.64 While no gross phenotypic 
anomalies were found in SPHK2 knockout mice, the embryonic and adult kidneys 
have not been extensively examined for histological abnormalities (personal 
communication – Dr. Richard Proia, National Institutes of Health). 
While considerable attention has focused primarily on the cellular activities of 
SPHK1, less is known about the function of SPHK2, particularly with respect to 
tumorigenesis. Varied roles for SPHK2 in tumorigenesis have been described, 
including its ability to induce cell cycle arrest and apoptosis or, in different cell types, 
to promote survival and proliferation. A mechanistic role for SPHK2 in the nucleus 
was first revealed upon the demonstration that it is co-immunoprecipitated with 
histone H3 (but not H4, H2B, or H2A), associates with HDAC1/2 in co-repressor 
complexes (including those at the promoters of p21 and c-fos), and results in 
increased acetylation at H3-K9, H3-K14 and H2B-K12.65 This function was shown to 
be due to SPHK2's phosphorylation of sphingosine and resulting inhibition of 
HDAC1/2. Other experimental studies have demonstrated an oncogenic role of 
SPHK2 in regulating the proliferation and survival of human acute lymphoblastic 
leukemia (ALL) cells. These effects were shown to occur via HDAC2-mediated 
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regulation of c-Myc.66 Specific systemic inhibition of SPHK2 (not affecting SPHK1 
function or expression) also resulted in a significant reduction in engraftment of 
human ALL cells into NOD/SCID mice. Thus, an exciting epigenetic role of SPHK2 in 
regulating gene expression is emerging, as is SPHK2's epigenetic role in cancer 
development.  
 
3.1.3. SPHK2 in the developing kidney 
In the mouse fetal kidney, several components of the sphingosine 1-phosphate 
signaling pathway are actively expressed, including the sphingosine kinases, S1P 
receptors (S1P1, S1P2, and S1P3), as well as S1P phosphatase and lyase, the 
enzymes involved in S1P metabolism. SPHK2 expression is predominately localized 
to the metanephric mesenchyme at higher levels than SPHK1 at E11, and gradually 
decreases to P4, indicative of a role in nephrogenesis.67 Support for a functional role 
also comes from pharmacological ablation of the sphingosine kinases in the 
embryonic kidney using small molecular inhibitors. Treatment of embryonic kidney 
explant cultures with sphingosine kinase inhibitors, thus blocking the production of 
sphingosine 1-phosphate, resulted in reduced branching morphogenesis during 
kidney development, underscoring the importance of S1P in development. 
 
3.2. MATERIALS and METHODS 
3.2.1 WTX524 family 
Following informed consent from all study participants, blood was drawn from 
members of the WTX524 family and peripheral blood DNA isolated for molecular 
analysis. The WTX524 family is a Hispanic, multigenerational Wilms tumor family with 
nine total cases. The ages of diagnosis ranged from 4-37 months, with an average of 
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15.3 months (considerably lower than the ~33 month age of diagnosis in familial 
Wilms tumor). Unilateral and bilateral tumors were diagnosed in the family, with the 
normal kidney tissue of affected children being “unusually rich in nephrogenic rests” 
(personal communication with B. Beckwith). Five individuals from the family were 
chosen for whole genome sequencing (Figure 5). Sequencing and bioinformatic 
analysis was performed as described in chapter 2.  
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3.2.2. Mutation Analysis of Candidate Genes 
Following the identification of candidate genes using next-generation sequencing, a 
complete mutation analysis of the genes was performed using Sanger sequencing of 
blood DNA from members of the family for segregation analysis. AmpliTaq (Life 
Technologies) and primers designed in Oligo (Molecular Biology Insights, Colorado 
Springs, CO) were used to amplify genomic DNA in a 25ul reaction volume for 35 
cycles. The PCR product was then treated with Exonuclease I and Shrimp Alkaline 
Phosphatase. Purified PCR products were then sequenced with target-specific 
primers and BigDye v1.1 (Life Technologies). Sequence reactions were purified with 
BigDye Xterminator purification kit and run on a Genetic Analyzer 3500 (Life 
Technologies). Sequence analysis was next performed with MutationSurveyor (Soft 
Genetics). If the candidate variant co-segregated with the affected/obligate carrier 
status, the mutation analysis was extended to one member of 48 Wilms tumor families 
to assess the frequency of candidate gene mutations in familial Wilms tumor samples. 
Additionally, qPCR was used to detect exonic deletions and duplications of the 
candidate gene. qPCR primers targeting exons (including exon/intron boundaries) 
were designed using Primer Express. Primer sets for mutation analysis of each gene 
by Sanger sequencing and qPCR are listed in Tables 2-3. 
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SANGER 
PRIMERS 
  
 
FORWARD Primer REVERSE Primer 
SPHK2 exon 2 AGCCTTCACTCCTATTAT 
GATTTTGTCTTTCCACAGTA
T 
SPHK2 exon 3 CACCTGTCTGAGCCTGTCTG CACATCCGGTCCTCTTGTCT 
SPHK2 exons 4-
6 GGGCTGGAAGTAACCTAA GCGCTCGGGATACAG 
SPHK2 exon 7a ACCCACAGTCAGTCAAGTAA GACGGGTGAGTGTAG 
SPHK2 exon 7b GACGGGTGAGTGTAG CTGCCACCACAACTCTA 
   TRPM4 exons 1-
2 TGTCCCTCTGTCCCCTTAT CACAGACCCAAACGCTCCTA 
TRPM4 exon 3 CCCTCAGAGAGAAGATAGGT CTCTACAGGAGCATGAACAC 
TRPM4 exons 4-
6 CCATGTGTCCACAGTTCC TCTCGACCAGACCAAACTAC 
TRPM4 exons 7-
9 ACTCCTGGGAAATGCG AAAATATTAAGAGGGGTAAA 
TRPM4 exon 10 ATGACCTTATGCCTATGATA AGAGAGGGAGGACAGCAC 
TRPM4 exons 
11-12 GCCCATCTCTTGTCCTTAAC TCGGGGAATTGTATG 
TRPM4 exons 
13-14 CCATCTCCAAACATTACTTCA GAGAGTGGCTGGTCAAG 
TRPM4 exons 
15-16 TTGCCTTTCACCACCGTTTC TCTCGCCATGTGATACACTG 
TRPM4 exon 17 AGACTGAGTTTCGGGTCA CTGAGTGGCGGACA 
TRPM4 exons 
18-19 CCGCGTCTGTCCATAC AAACTGCTGGCGAGTGTA 
TRPM4 exon 20 CGCCTGGCTAACAGT ATCAGAGTTCAGGGACTAAA 
TRPM4 exons 
21-25 TACAGGCGTGACCAA AAGGGAGGAAACGGACTC 
   GADD34 exon 2 CACACCGGGAGTGTTGT 
AAATAGAATCTGGGCTCTCA
G 
GADD34 exon 3 ATAGAGAATCCCGTGACAGT TACAGACGCTGCTCGCTACA 
 
Table 2. Primer sets for mutation analysis of three candidate genes by Sanger 
sequencing. 
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qPCR PRIMERS 
  
 
FORWARD Primer REVERSE Primer 
SPHK2 exon 1 
CTCTACCACGATCCGGA
CTTCT TTGGACGTTGCGCTTGTTC 
SPHK2 exon 2 
CCAGGGTCCCGTTGATG
TAA 
ATGAGGATCTTGGCTTTTAG
ATGGT 
SPHK2 exon 3-4 
GTCTGAGCCTGTCTGTC
TCTGATG 
CTGTGGGAAGGGAGGAGA
GAA 
SPHK2 exon 5-6 
CTGAGTCCTAAGGGAGC
AAAGTG 
CTGTCGTTCTGAAGTGGGA
TACC 
SPHK2 exon 7 
TCCGTCCCCAATCTAAA
AAGC 
GCTGGAAGTGCTGGAGTCT
GA 
   
TRPM4 exons 1-2 
CCGGATCTGTGGAGTCA
ACTATG TGCCCTCTCACCCCACTTC 
TRPM4 exon 3 CGGCCCCCGTGAAGTC CCGCAGTGGCCATGGA 
TRPM4 exons 4-6 
AGACCAGGGCGTCTCCT
CAT 
CGGAATAGAGACACCCTCA
TCAA 
TRPM4 exons 7-9 
CCAGCCACGAGGAGACA
TG 
GGTGAATATCCTGCCTTTTC
TGA 
TRPM4 exon 10 
GTTCCAAGCCACAGCCA
AA 
TTGTCCCCTCTCCCTCTAAT
CC 
TRPM4 exons 11-12 
GATGCAGGAGCGCCAA
GT CCCTGGAGCGACCTGCTT 
TRPM4 exons 13-14 
CCTCACCTCACTGCTGC
GATA 
TCACACCCTCACCCTACTC
CTT 
TRPM4 exons 15-16 
GACAGGCCCTTCCCCAT
TAA 
TTCTCTTCCCCTCATTTCTT
GCT 
TRPM4 exon 17 
AGTGGGCAGGAAGGAT
GAGA CTCGCCGACAGCTGGAA 
TRPM4 exons 18-19 
CCGTGAAAACCATGAAG
TCGAT 
ACACTTGACCCTTGTGGCA
TCT 
TRPM4 exon 20 
AGGAGGGTGTGCCCAG
AAG 
TCACCCCATCTCTGAATGTC
TCT 
TRPM4 exons 21-25 
GCCCCGCTCTCACTTCT
G 
ATCGGTGCATAAGGAGAAC
TTTCT 
   GADD34 exon 1 TGGGATGGGAACCGATAAGA TCGAAACCCCGCCTCTCT 
GADD34 exon 2 CCCAAGACTCCAACTCAATTAAAAA GCTCAAGCGCCCAGAAAC 
GADD34 exon 3 CGCTGCTCGCTACAAATCAA GGGAGGCGTGGCTGAGA 
 
Table 3. Primer sets for the detection of exonic deletions in candidate genes by 
qPCR. 
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3.2.3. Gene Expression by qPCR 
 
SYBR Green (Applied Biosystems) was used for analysis of SPHK2 gene 
expression. RNA was isolated from lymphoblastoid cell lines using Trizol, quantified 
and used for cDNA synthesis using MultiScribe Reverse Transcriptase and PCR 
Master Mix according to the protocol (Invitrogen). Forward and reverse primers for 
detecting expression levels of specific genes were designed using Primer Express 
(Applied Biosystems). Quantification of expression was performed using SYBR green 
and the ABI 7900 HT sequence detection system (Applied Biosystems). Gene specific 
Ct values were compared across samples relative to GAPDH levels and calculated as 
fold differences to a control reference value whose expression was designated as 1. 
qPCR primer sequences are listed in Table 4. 
 
 
Forward primer Reverse primer 
p21 CGATGGAACTTCGACTTTGTCA 
GCACAAGGGTACAAGACA
GTG 
c-fos CACTCCAAGCGGAGACAGAC 
AGGTCATCAGGGATCTTG
CAG 
c-myc GGCTCCTGGCAAAAGGTCA 
CTGCGTAGTTGTGCTGAT
GT 
SPHK2-L   ATGAATGGACACCTTGAAGCAG 
 
CATGGCCTTAGCCCTGAC
CAG 
SPHK2-Total  CTGTCTGCTCCGAGGACTGC 
 
CAAAGGGATTGACCAATA
GAAGC 
 
Table 4. qPCR primers for expression profiling of SPHK2 isoforms and target genes. 
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3.2.4. Generation of SPHK2 constructs 
Human SPHK2-S and SPHK2-L cDNA was amplified from a SPHK2 image 
clone (Origene, SC113181) using the primers listed in Table 5. A PCR product of the 
correct size was gel purified and enzymatically treated with XbaI and XhoI restriction 
enzymes for 1 hr at 37*C. This digested PCR product was then treated with Mung 
Bean nuclease to produce blunt ends, as well as shrimp alkaline phosphatease at 
37*C for 30 min. The product was then ligated into a pcDNA3.1 V5/His expression 
vector (Life Technologies). The ligation reaction was performed at 16*C overnight, 
followed by transformation into competent E.coli cells overnight. Colonies were 
screened by cutting with EcoRI at 37*C for 30min, followed by gel electrophoresis. 
Those that appeared to have integrated the plasmid + insert of the correct size were 
grown overnight at 37*C and screened by PCR for the correct insertion of the plasmid. 
QuikChange site directed mutagenesis was performed using manufacturer’s protocol 
to introduce the R100W and R136W mutations. Sanger sequencing confirmed the 
introduction of the mutation. Plasmids containing the mutation were grown overnight 
at 37*C and used for Midi-prep of DNA. The same procedure was repeated to 
generate mouse SPHK2 constructs using mSPHK2 cDNA and mouse-specific SPHK2 
primers. Site directed mutagenesis was used in the generation of mutant mouse 
SPHK2 (R100W – the equivalent of the human R136W mutation) constructs. 
 
3.2.5. Transient and stable-transfected cell lines 
To generate transient and stable-transfected cells for functional experiments, 
MCF7 (a human breast cancer cell line) and M15 (a mouse renal mesenchymal cell 
line) cells were seeded in 6-well plates and incubated at 37*C overnight. Transfection 
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using Lipofectamine 3000 (Life Technologies) was performed at a ration of 3:1 (lipid 
complex/DNA) and incubated overnight. The following day, the transfection reagent 
was removed and cells were used for 1) transient expression experiments, or 2) 
seeded in 10cm culture plates along with 1ug/ml G418 for 2 weeks to select for stable 
transfectants. Following selection with G418, cells stably expressing the plasmid were 
seeded sparsely into 10cm plates for isolation of single colonies. Single colonies were 
trypsinized and seeded into 24-well culture plates, along with media supplemented to 
G418. Once the colonies were confluent, they were trypsinized and seeded into 12-
well plates. The process was repeated using larger culture volumes until enough cells 
were obtained for experiments. 
M15 cell lines with the R101W mutation (analogous to the human SPHK2R136W) 
introduced into the endogenous locus of SPHK2 were generated using CRISPR/Cas9 
genome engineering. These cell lines were a gift from E. Cristy Ruteshouser and 
used for gene expression studies described below.  
 
3.2.6. Western Blot Analysis 
SPHK2-stable transfected MCF7 cells were washed with ice-cold PBS and 
scrapped in SPHK2 lysis buffer containing 50mM HEPES, 150mM NaCl, 1mM EDTA, 
1% Triton X-100, 2mM sodium orthovanadate, 4mM sodium pyrophosphate, 100mM 
NaF, and 1:500 protease inhibitor mixture. Lysates were sonicated and centrifuged at 
14,000 x g for 15 min and quantified with the BioRad protein assay and 
spectrophotometer. Equal amounts of protein lysates (20ug) were used for 
subsequent analysis. Protein lysates were denatured for 10 min at 99 °C with β-
mercaptoethanol before loading into BIORAD Mini-PROTEAN TGX Precast Gels with 
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Laemmli running buffer at 90 volts for 2 hrs. Following gel electrophoresis, proteins 
were transferred to nitrocellulose membranes using BIORAD Mini Trans-Blot cell 
assembly run at 22V at 4 °C overnight. Membranes with bound proteins were blocked 
for 1 hr in 5% milk in TBST (1X Tris buffered saline/0.1% Tween-20) followed by 
incubation with primary antibody in 5% milk in TBST for 1 hr at room temperature. 
Membranes were then washed 3 times with TBST, followed by a 1 hr incubation with 
secondary antibody (donkey anti-rabbit IgG, GE Healthcare, NA934V) diluted 1:5000 
in 5% milk in TBST at room temperature. Following 3 washes in TBST, membranes 
were developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) according to the protocol.  
3.2.7. Immunofluorescence 
For immunofluorescence studies of cultured cells, cells were plated in 8-well chamber 
slides (LabTek) and allowed to adhere overnight before fixation with 4% 
paraformaldehyde for 15 min. The slides were then incubated with 0.5% Bovine 
Serum Albumin in in PBS for 1 hr, followed by washing three times with PBS. Primary 
antibodies (anti-V5, 1:1000) were added to the chamber slides followed by a 1 hour 
incubation at room temperature. Chamber slides were then washed three times in 
PBS and incubated with secondary antibodies Alexa Fluor-488 (Invitrogen) for 1 hr in 
the dark. Subsequently, the slides were washed three times in PBS and stained using 
ProLong Gold anti fade reagent with DAPI (Invitrogen) and allowed to air-dry 
overnight at 4 degrees in the dark. 
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3.2.8. Proliferation Assay 
To measure proliferation, MCF7 stably-transfected cells and M15R101W cells 
were plated on 8-well chamber slides (LabTek) and incubated overnight. Detection of 
a modified thymidine analogue (EdU) incorporated into newly synthesized DNA was 
performed using the Click-iT Plus EdU Alexa Fluor 488 Imaging Kit (C10637, Life 
Technologies) following manufacturer’s protocol. Images were captured using an 
Olympus BX60 fluorescence microscope and quantified using MetaMorph Microscopy 
Automation and Image Analysis Software. 
 
3.2.9. Apoptosis Assay 
Apoptosis of M15 cells was performed using the DeadEnd TUNEL assay 
(Promega) according to manufacturer’s instructions with the following modifications: 
1) Cells were plated in 8-well chamber slides (LabTek) instead of cover slips. Images 
were captured using an Olympus BX60 fluorescence microscope. 
 
 
 
3.3. RESULTS 
3.3.1. Whole genome sequencing identifies candidate familial Wilms tumor 
predisposition gene: SPHK2 
To identify the 19q FWT gene, we sequenced the whole genomes of five affected 
individuals and one married-in control within a large multigenerational WT family. The 
coverage was approximately 30X across all members (Figure 6). We first looked for 
shared variants between the 5 affected individuals, and filtered out all variants that 
were in common with the married-in control. This resulted in 206,860 variants 
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remaining across the entire genome. After excluding variants previously found in 
dbSNP or those present at a frequency of >1% in 1000 Genomes Project data, we 
were left with 20,517. A total of 18 exonic variants were identified from this analysis, 
of which 10 variants were nonsynonymous and 8 were synonymous (Table 6). Of 
these, we observed 1 in the 19q linked region (Table 7). The other variants we 
identified were eliminated from further consideration because they were 1) located 
outside of the 19q linked region and 2) not plausible candidates for having an obvious 
role in kidney development. In addition to SPHK2, two candidate variants were 
identified within the linked region that were novel at the time of discovery. However 
they have since been reported with minor allele frequencies greater than 1%. A 
comprehensive mutation analysis of the two genes, TRPM4 and PPP1R15A, 
excluded these genes as candidate familial Wilms tumor predisposition genes based 
on 1) identification of potentially deleterious variants coming from the unaffected 
married-in parent and absence of the variant in the affected parent, and 2) their 
increased population frequency with the continued development of variant databases. 
Our analysis left us with one candidate, sphingosine kinase 2 (SPHK2).   
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Figure 6. Coverage across the whole genome for six members of the WTX524 family. 
The coverage was approximately 30X for all members, which is sufficient to call 
germline variants at high confidence. 
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Table 6. Shared single nucleotide variants (SNVs) and insertions/deletions (indels) 
across the entire genome from five WTX524 family members with Wilms tumor. 
Further filtering using data from the married-in control resulted in the variant numbers 
listed on this table. Included in the analysis are those shared across the entire 
genome, as well as novel and rare (minor allele frequency < 1%) variants occurring  
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Table 7. Candidate familial Wilms tumor predisposition genes following the 
application of all filtering criteria. Variants listed here are those that are novel/rare, 
shared by five affected Wilms tumor family members, and not found in the spousal 
control. Conservation scores are represented using PhyloP. Expression in fetal kidney 
(FK) was determined using gudmap.org.   
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The SPHK2 variant (chr19:49129514, GRCh37/hg19, c.772C>T, p.R136W) 
was present in roughly 50% of the sequence reads indicative of a heterozygous 
germline variant and occurs at an evolutionarily conserved amino acid residue 
indicated by a PhyloP score of 0.999 (Figure 7-8). Substitution of an arginine for a 
tryptophan at this position is predicted to be deleterious (SIFT-0, PolyPhen-0.999). 
This variant was not identified in >60,000 individuals whose exome data were 
included in the Exome Variant Server (http://wvs.gs.washington.edu/EVS/). The 
R136W mutation does not fall within a currently defined domain of SPHK2, although it 
should be noted that SPHK2 is poorly characterized at this point. Interestingly, the 
R136W mutation occurs within six amino acid residues from the nuclear localization 
sequence.  
 
3.3.2. SPHK2R136W co-segregates within the family 
We confirmed the co-segregation of the germline, heterozygous mutation in all 
affected and obligate carrier members of the family using Sanger sequencing (Figure 
9). In total, 17 mutation carriers were identified, 8 of which developed Wilms tumor 
(47%). The variant was not identified in 11 other family members tested, 7 of which 
were married-in, spousal controls. Sequencing this same exon in a tumor sample from 
the family showed heterozygosity for the mutation, indicating the wildtype allele was 
not lost somatically in the tumor. Sanger sequencing of the entire SPHK2 coding 
region was then performed in the tumor sample for the assessment of possible 
compound heterozygosity. No somatic SPHK2 mutations were identified in the tumor. 
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Figure 7. Visualization of the region surrounding the SPHK2 variant (R136W) using 
the Integrative Genomics Viewer (IGV).  The variant allele (T) is present in roughly 
50% of the sequence reads, indicative of a heterozygous variant. This figure is 
representative of the sequence reads from five affected individuals in the WTX524 
family. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Amino acid sequence conservation of the R136W variant and surrounding 
residues. Analysis by PhyloP was also used for conservation. 
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Figure 9. Cosegregation of the R136W variant by Sanger sequencing. Primers 
targeting exon 3 of SPHK2 were used to assess cosegregation within the family. 
These sequence traces represent the unaffected and affected/obligate carriers whose 
DNA was assessed in the WTX524 family. 
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3.3.3. Comprehensive SPHK2 Mutation Analysis in Familial Wilms tumor 
A complete mutation analysis of all seven exons of SPHK2 was performed in 
one member from 47 additional Wilms tumor families. This mutation analysis included 
Sanger sequencing, as well as qPCR for the detection of exonic deletions (Table 8). 
No germline deletions were detected by qPCR. However, five variants, either novel or 
with a minor allele frequency of less than 1%, were identified in six Wilms tumor 
families by Sanger sequencing. Two of these alterations, P83P (rs151257086) and 
L249L (rs116785119), were synonymous mutations not predicted to alter splicing 
(ALAMUT). A novel, heterozygous 5’ UTR variant (49123707A>C) was found in one 
WT family, however its affect on SPHK2 expression is unknown. Additionally, a rare 
missense mutation (p.G601A, rs61751862) was identified in two Wilms tumor families. 
This rare variant has a population frequency of 0.000014 and has been reported in 
1/69,600 individuals (Exome Aggregation Consortium, exac.broadinstitute.org). Like 
the R136W mutation, the G601A also does not occur within a currently defined 
domain of SPHK2. All germline missense mutations identified in familial Wilms tumor 
samples were predicted to be damaging by at least one of the prediction algorithms 
and segregated with the affected/obligate carrier status in each family. 
 
 
 
 
 
 
 
!! 50!!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Comprehensive SPHK2 mutation analysis, including Sanger sequencing and 
qPCR, of all seven SPHK2 exons in one member of 47 Wilms tumor families identified 
novel/rare nonsynonymous and synonymous germline mutations. 
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3.3.4. SPHK2 Mutation Analysis in Sporadic Wilms tumor 
Many cancer genes have been identified whose germline mutation predisposes 
to cancer and whose somatic mutation also plays key roles in the etiology of non-
familial cancers, which account for the majority of cancers in the general population. 
To assess the frequency of SPHK2 variants in non-familial tumors, we extended our 
screening to 175 sporadic Wilms tumors. Sanger sequencing of 175 sporadic Wilms 
tumor samples was performed using primers targeting each exon of SPHK2. Eleven 
variants (5 missense, 6 synonymous) were identified in this analysis (Table 9). The 
five nonsynonymous variants were all previously reported in variant databases at a 
frequency of less than 1%, and all were predicted to be pathogenic by at least one 
prediction algorithm. Sanger sequencing of the corresponding blood sample from 
each individual was performed to determine if the variants occurred in the germline or 
were somatically acquired. The only somatic variant was a novel synonymous 
mutation (F135F) identified in one tumor. The potential impact of synonymous 
variants on splicing was assessed using ALAMUT. One variant, P380P, was predicted 
to activate a cryptic splice site in exon 7 of SPHK2. Of the five tumors in which a 
SPHK2 variant was identified, three contained an additional alteration, including 
somatic CTNNB1 mutation (Ser22Cys), germline WT1 mutation, and loss of the 
wildtype SPHK2 allele. 
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Table 9. Comprehensive SPHK2 mutation analysis of all seven SPHK2 exons in 176 
sporadic Wilms tumor samples identified novel/rare nonsynonymous and synonymous 
SPHK2 mutations. 
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3.3.5. Functional impact of SPHK2 mutation  
3.3.5.1. SPHK2-short is predominant form in fetal kidney 
Before investigating the functional significance of the SPHK2 R136W variant 
identified in the WTX524 family, we confirmed expression of SPHK2 in human fetal 
kidney using human fetal kidney RNA purchased Clontech Laboratories. Consistent 
with results from mouse expression profiling, we observed expression of SPHK2 in 
the embryonic kidney. It was previously reported that SPHK2-L was the predominant 
isoform expressed in most human adult tissues and cell lines screened to date except 
the kidney and brain, where the expression of both short and long isoforms appeared 
equal. Using isoform-specific qPCR primers, we observed 5-fold greater expression (p 
= 0.001) of SPHK-S in the human fetal kidney, suggesting the short isoform has a 
more significant role in kidney development (Figure 10).  
 
3.3.5.2.  SPHK2R136W impairs nuclear localization and alters gene expression in 
MCF7 cells 
The SPHK2 variant we identified in the family has not been reported to date. 
As a result, there is no data describing the functional impact of this nonsynonymous 
mutation on protein function. Moreover, SPHK2 has not been as extensively studied 
as SPHK1, and literature describing protein domains and their respective functions 
are lacking. Although the mutation we identified within the family does not fall within a 
currently-defined domain of SPHK2, it is in close proximity (within 6 amino acid 
residues) to a previously characterized nuclear localization signal.  
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Figure 10. Expression of SPHK2-Total and SPHK2-Long in human fetal kidney. 
Primers were designed to target a region common to both isoforms (termed SPHK2-
total) and a region specific to the long isoform (SPHK2-Long). The difference between 
the two represents expression of the SPHK2-short isoform. 
 
 
 
 
!! 55!!
This ability of SPHK2 to localize to the nucleus is crucial for its role in epigenetic 
regulation of gene expression.65 In order to determine if this alteration is functionally 
significant as suggested by a number of prediction algorithms, we generated SPHK2 
constructs (SPHK2-Long and SPHK2-short) containing the same mutation we 
identified in the family to assess the impact of the mutation on subcellular localization. 
Using site-directed mutagenesis, SPHK2R100W was introduced into the SPHK2-short 
isoform, and the analogous SPHK2R136W was introduced into the SPHK2-long isoform. 
These mutant constructs, as well as the wildtype controls, were transiently transfected 
into MCF7 cells. We chose this cell line because 1) it expresses SPHK2 at a low level 
(so endogenous wildtype protein is less likely to obscure the effect of the exogenous 
mutant protein) and 2) it was the cell line used for the initial characterization of 
SPHK2’s role in the nucleus to interact with HDAC1/2 and histones and to regulate 
gene expression in an HDAC1/2- dependent manner. This allowed us to directly relate 
our data on SPHK2R136W to published findings. Expression of the constructs at the 
mRNA and protein levels were confirmed (Figure 11). Using immunofluorescence, we 
observed a significant reduction (p = 0.029) of mutant SPHK2 in the nucleus 
compared to the cytoplasm (Figure 12a). As expected, the expression of target genes 
(p21 and c-myc) was significantly increased when wildtype SPHK2 was expressed in 
MCF7 cells, an observation consistent with previous reports (Figure 12b). In contrast, 
expression of mutant SPHK2 resulted in a significant reduction of p21 and c-myc, 
consistent with altered subcellular localization of mutant SPHK2. 
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Figure 11. Expression of wildtype and mutant SPHK2 was confirmed at the mRNA 
and protein levels using qPCR and western blotting, respectively, in MCF7 cells 
transfected with human SPHK2 overexpression constructs.  
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Figure 12a. Immunofluorescence using DAPI (nuclei) and anti-V5 (SPHK2) 
antibodies to visualize wildtype and mutant SPHK2 localization after transient 
transfection in MCF7 cells. Intensity of the anti-V5 signal from the nucleus and 
cytoplasm was quantified with ImageJ, and presented as the nuclear/cytoplasm ratio.  
 
 
 
 
 
 
 
 
 
 
Figure 12b. Expression of SPHK2 target genes in MCF7 cells were assessed by 
qPCR after transfection with wildtype and mutant SPHK2 expression constructs. 
(p values * = <0.02; # = 0.03)  
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3.3.5.3.  SPHK2R101W impairs nuclear localization in M15 cells 
Our previous data suggests that the SPHK2 R136W mutation identified within 
the WTX524 family alters nuclear localization and subsequent gene expression in 
MCF7 cells. In order to investigate the significance of the variant in a system more 
relevant to that of kidney development, wildtype and mutant mouse SPHK2 
expression constructs were generated and used for transfection experiments in a M15 
cell line, a renal mesenchymal cell line similar to the cells in the embryonic kidney that 
are thought to give rise to Wilms tumors. Wildtype and SPHK2R100W (analogous to the 
human SPHK2R136W) constructs were transiently transfected into M15 cells and 
subcellular localization of SPHK2 protein examined using immunofluorescence. We 
observed a significant reduction in SPHK2R100W nuclear localization compared to 
wildtype protein (Figure 13). These results were consistent with the analogous 
experiment in MCF7 cells, providing confirmation of our results in two experimental 
systems. 
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Figure 13. Immunofluorescence assay shows reduced nuclear accumulation of 
SPHK2R101W compared to wildtype SPHK2. Intensity of the anti-V5 signal from the 
nucleus and cytoplasm was quantified with ImageJ and presented as the 
nuclear/cytoplasm ratio.  
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3.3.5.4.  SPHK2R101W alters expression of kidney developmental genes. 
 Data from our previous experiments suggest that SPHK2R136W alters gene 
expression following mislocalization of mutant SPHK2 to the nucleus. These studies 
used overexpression of SPHK2 in MCF7 cells, which express very low levels of 
SPHK2. In order to assess the effect of this mutation in a fetal kidney experimental 
system with no manipulation of gene expression level, we examined expression of 
genes expressed during kidney development using cells in which the SPHK2R101W 
mutation was introduced into the endogenous locus of SPHK2 via the Clustered 
Regularly Interspaces Short Palindromic Repeat (CRISPR/Cas9) system. M15 cells 
carrying the homozygous SPHK2R101W alteration were generated previously in our lab 
(E.C. Ruteshouser). Gene expression profiling of selected kidney developmental 
genes (CDN11, CSRP1, GDNF, LHX1, MLL5, NR2F2, OSR1, SPRY1, EYA1, 
FOXD1, WNT4, WT1) was assessed in M15wt and M15R101W cells using qPCR (Figure 
14). Of these genes, EYA1 was significantly upregulated in mutant cells compared to 
wildtype M15 cells. One disadvantage of CRISPR/Cas9 mutagenesis is the possibility 
of off-target activity due to sequence similarity of the guide RNA with other regions of 
the genome. Although these target sites (predicted using the CRISPR Design Tool)  
were screened by PCR amplification and Sanger sequencing and revealed no off-
target activity, our analysis included three M15R101W clones generated simultaneously 
with CRISPR/Cas9 to account for potential off target effects not predicted by the 
prediction software. 
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Figure 14. Gene expression profiling of 12 genes expressed during kidney 
development using wildtype M15 cells, as well as three M15 cell lines containing the 
R101W mutation generated by CRISPR/Cas9. EYA1 was consistently upregulated in 
each of the three mutant cell lines, whereas other genes do not appear to be altered 
in SPHK2 mutant cells. The expression of EYA1 in each mutant clone was 
significantly upregulated compared to wildtype (p value = <0.01). 
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3.3.5.5.  SPHK2R100W does not affect proliferation or apoptosis 
There are several reports of phenotypic effects observed upon SPHK2 
overexpression, down-regulation, or inhibition in cell lines. Wildtype SPHK2 has been 
shown to promote both proliferation and apoptosis, depending on the cell type used. 
These contradictory results appear to be due, at least in part, to the different 
subcellular localization of SPHK2 and its product, S1P, between cell types. We 
investigated the effect of mutant SPHK2 on proliferation in M15 cells containing the 
SPHK2 mutation knocked in to the endogenous locus and noted no significant 
difference between wildtype and mutant SPHK2 cells, suggesting the genes regulated 
by SPHK2 are not involved in cell proliferation of M15 cells (Figure 15). Additionally, 
apoptosis was also examined in wildtype and mutant M15 cells, and no significant 
differences were observed (Figure 16). 
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Figure 15. Cell proliferation assay using wildtype M15 cells and three SPHK2R101W 
mutant clones. Proliferation was measured by incorporation of EdU, a thymidine 
analogue, into proliferating cells. 
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Figure 16. Apoptosis assay using wildtype M15 cells and three SPHK2R101W mutant 
cell lines. No differences in apoptosis between wildtype and mutant cells were 
detected. Incorporation of fluorescein-12-dUTP at 3’-OH ends of fragmented DNA 
was visualized by fluorescence microscopy. 
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3.4. DISCUSSION!  
Next-generation sequencing has recently facilitated the discovery of genes 
involved in sporadic Wilms tumor cases, resulting in significant progress in 
understanding how aberrant development leads to cancer. However, the gene 
mutations predisposing to familial Wilms tumor are generally unknown. Familial Wilms 
tumor is genetically heterogeneous, and in order to understand the mechanisms of 
tumor formation, the mutated gene(s) involved must first be identified. Fortuitously, 
next-generation sequencing allows for cost-efficient, high throughput surveying of the 
entire genetic landscape in an unbiased manner to identify genes causing disease.  
Following a whole genome sequence analysis of members of a large 
multigenerational 19q-linked Wilms tumor family, we identified variants shared by 
affected/obligate carriers in the family and analyzed their potential to be candidate 
Wilms tumor predisposition genes. Using this family based sequencing approach, 
which included 5 affected family members and 1 spousal control, we were able to 
significantly reduce the number of candidate variants for further investigation. Of the 
10 exonic variants identified from this analysis, one was located within the 19q linked 
region previously characterized by our lab. As a result, we have successfully identified 
mutations in SPHK2, which encodes sphingosine kinase 2, as a candidate familial 
Wilms tumor predisposition gene.  
The SPHK2 variant (R136W) identified in our study is novel, co-segregates 
with the affected/obligate carrier status in the family, occurs at an evolutionarily 
conserved amino acid residue, and is predicted to be deleterious by several prediction 
algorithms. Identification of SPHK2 mutations in other Wilms tumor families, as well 
as sporadic Wilms tumor cases, further implicates SPHK2 as a gene contributing to 
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Wilms tumor development. SPHK2 variants are noted in a variety of cancers in the 
COSMIC database, and these are almost exclusively missense mutations. These data 
argue that the SPHK2 mutations are functionally significant due to encoding a protein 
with an altered function. Our data suggests that the SPHK2R136W is indeed deleterious 
to protein function by reducing nuclear localization in MCF7 and M15 cell lines. 
Because mutant SPHK2 can not properly localize to the nucleus, target gene 
expression is altered.  
SPHK2 is expressed in the embryonic kidney, with its highest levels occurring 
in the metanephric mesenchyme during early nephrogenesis. Therefore, SPHK2 is 
highly expressed in the cells thought to give rise to Wilms tumors. Previous reports 
show significantly increased SPHK2 mRNA in WiT49 cell and Wilms tumor samples 
compared to matched normal tissues, indicating that SPHK2 may have a functional 
role in Wilms tumor. Not only is SPHK2 actively expressed in the fetal kidney, but 
components of its nuclear co-repressor complex such as HDAC1/2, are differentially 
expressed during nephrogenesis as well. Interestingly, HDAC1/2 has only recently 
been recognized as critical for kidney development. Inhibition of histone deacetylase 1 
and 2 in the metanephric kidney results in the specific downregulation of genes 
driving differentiation (WT1, EYA1, SALL1). SPHK2 has an important role in 
chromatin regulation,65 which is becoming increasingly recognized as playing a major 
role in tumorigenesis. SPHK2 itself has recently been demonstrated to have a 
significant role in leukemogenesis through its effect on HDAC2-dependent regulation 
of c-Myc expression. Our identification of SPHK2 mutations in both familial and 
sporadic Wilms tumors (Figure 17), and the observation that the SPHK2R136W results 
in modification of gene expression, suggests that, like mutations in WT1 (encoding a  
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transcription factor), mutant SPHK2 alters gene expression in the developing kidney 
which results in the presence of cells predisposed to malignant transformation. In the 
case of SPHK2, the mechanism for this altered expression would be via altered 
chromatin regulation. Interestingly, as more pediatric sequencing studies are being 
completed, the number of mutations in genes involved in chromatin regulation and 
remodeling have outweighed the relative lack of mutations in classic oncogenes and 
tumor suppressors in childhood cancers, suggesting epigenetic events contribute 
more frequently to the incidence of pediatric cancer cases.  
Analysis of tumors from families linked to chr17q, a region containing another 
familial Wilms tumor predisposition gene (known as FWT1), showed no loss of 
heterozygosity of polymorphic microsatellite markers within the 17q-linked region.68 
This was also observed with the 19q-linked tumors as well, indicating that these 
genes might not function as classical tumor suppressors. In our analysis, the SPHK2 
R136W mutation was heterozygous in the germline, as well as in two tumor samples 
from affected members of the family. Furthermore, mutation analysis of all seven 
exons of SPHK2 showed no additional somatic mutation in either tumor. Likewise, all 
SPHK2 variants we identified in familial and sporadic cases were heterozygous as 
well, with the exception of one sporadic case (germline P654H, tumor specific LOH). 
Taken together, this suggests that mutation of the familial Wilms tumor predisposition 
genes may be necessary for the initiation of Wilms tumors, but are not sufficient to 
result in disease. Mutations elsewhere in the gene (regulatory or intronic regions), in 
additional genes, or the action of modifier genes might be necessary for tumor 
development from precursor lesions.  
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As mentioned previously, the kidneys of members of the Wilms tumor family carrying 
the germline SPHK2 mutation were "unusually rich" in nephrogenic rests, a precursor 
to Wilms tumor. In our lab’s existing mouse model of Wilms tumor, in which mosaic 
somatic ablation of Wt1 in the context of upregulation of the fetal mitogen Igf2, we 
observe both tumors and foci of undifferentiated mesenchyme, like nephrogenic rests. 
Mice with mosaic somatic ablation of Wt1 in the absence of Igf2 upregulation also 
display such foci. Based on these data and the role of SPHK2 in epigenetic regulation 
of gene expression, we speculate that the missense mutation has an effect on normal 
metanephric mesenchyme differentiation such that foci of undifferentiated 
mesenchyme (nephrogenic rests) develop. This is consistent with our data 
demonstrating a significant increase in expression of Eya1 in a M15 cell line in which 
the R100W mutation was knocked into the endogenous Sphk2 locus. Eya1, along 
with Wt1 and Pax2, is a transcription factor expressed early in kidney development in 
the metanephric mesenchyme and is involved in the maintenance of nephron 
progenitors.101 Deletion of Eya1 in this population of cells results in premature 
differentiation and depletion of nephron progenitor cells by acting upstream of Six2. 
We can speculate that the increased expression of EYA1 contributes to the formation 
of nephrogenic rests by maintaining the self-renewal of nephron progenitor cells, as 
deletion of Eya1 results in the loss of Six2 expression and premature differentiation of 
the progenitors. 
In our model, SPHK2 mutation carriers are at a higher risk of Wilms tumor 
development due to the presence of nephrogenic rests. Neoplastic transformation of 
these precursors then proceeds following an additional alteration acquired within the 
nephrogenic rest, such as upregulation of Igf2, an alteration commonly observed in 
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Wilms tumors, but which, alone, is not sufficient for tumor development. Additional 
experiments using mouse models will further clarify this hypothesis. However, it is 
clear that SPHK2 and sphingolipid metabolism is an emerging pathway in cancer 
development. Our identification of SPHK2 as a candidate familial Wilms tumor 
predisposition gene and our analysis of the functional significance of its mutation in 
mouse mesenchymal cells suggests a role in regulation of kidney developmental 
genes.  
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CHAPTER 4: Identification of novel DICER1 mutations in Wilms 
tumor families 
 
4.1.  INTRODUCTION 
 Since the identification of DICER1 mutations in rare Wilms tumor cases in 
2011, studies using next-generation sequencing have found that the microRNA 
processing pathway is sometimes mutated in Wilms tumors. As a result, these studies 
have provided a glimpse into the mechanism of Wilms tumor development through 
altered production of small RNAs regulating gene expression. The enzymes 
responsible for processing these microRNAs are crucial for mature microRNA 
expression and have thus emerged as key players of nephrogenesis and Wilms 
tumorigenesis. 
 
4.1.1. MicroRNAs 
MicroRNAs (miRNAs) are small, ~22 nucleotide noncoding RNAs that regulate 
gene expression post-transcriptionally.69 With important roles in cellular processes 
such as differentiation, development and the cell cycle, dysregulation of miRNA 
biogenesis can serve as the key driving mechanisms of tumor formation.70-74 Recent 
studies have identified miRNAs and the enzymes involved in their production as vital 
factors for the proper development of the kidney.75 More than 170 miRNA families 
present in the embryonic kidney have been identified by deep sequencing. These 
miRNAs, including members of the miR-200 family, regulate the expression of genes 
critical for the formation of the mature kidney, as well as support differentiation and 
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survival of nephron progenitors, podocytes, juxtaglomerular cells and ureteric 
epithelium.76-79 
The biogenesis of miRNAs proceeds in a stepwise progression that is 
subjected to multiple levels of regulation (Figure 18). This process begins when long, 
primary transcripts (pri-miRNAs) are transcribed in the nucleus by RNA Polymerase II. 
Interaction of pri-miRNAs with the nuclear microprocessor complex consisting of 
DiGeorge syndrome critical region 8 (DGCR8) and DROSHA, the nuclear counterpart 
of DICER1, results in the cleavage of the RNA to a 60-70 nucleotide pre-miRNA.80-83 
These hairpin-folded pre-miRNAs are exported to the cytoplasm by exportin 5 
(XPO5).84-86 In the cytoplasm, pre-miRNAs interact with DICER1, where they are 
cleaved into ~20 nucleotide double stranded RNAs.87 These ~20-nucleotide mature 
miRNAs are loaded into the RNA-induced silencing complex (RISC), where they bind 
to target mRNAs. Each miRNA can regulate the expression of 50-100 mRNAs by 
binding through sequence complementarity of its 8-nucleotide seed sequence to 
target sites occurring in the 3’-UTR of genes and silencing by miRNA-mediated 
degradation or disruption of the ribosomal complex. Consequently, proper cleavage of 
the miRNAs by DICER and DROSHA is important in maintaining the correct seed 
sequence for recognition of target mRNAs. 
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Figure 18. Micro RNA biogenesis pathway. miRNAs are transcribed in the nucleus by 
RNA Polymerase II as pri-miRNAs. Interaction with Drosha and DGCR8 results in the 
cleavage of the pri-miRNA into a shorter ~60-70 nucleotide pre-miRNA. Pre-miRNAs 
are exported to the cytoplasm by Exportin-5, where they interact with Dicer and 
TRBP2 for further cleavage into ~22 nucleotide mature miRNAs. Each mature miRNA 
is estimated to silence the expression of up to 100 target mRNAs.  
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4.1.2. The miRNA pathway in Wilms tumor 
The miRNA pathway has recently emerged as a critical regulator of 
nephrogenesis.17,32 Perturbation of this pathway in specific cell types and precise 
times during renal development results in abnormal renal morphogenesis and cancer. 
Indeed, mutations in components of the miRNA pathway have recently been identified 
in a subset of Wilms tumors. Exome sequencing of poor outcome Wilms tumors, as 
well as high-risk blastemal Wilms tumors revealed heterozygous mutations in 
DROSHA and DGCR8 in 15% of these selected tumors. Heterozygous mutations in 
the RNase IIIb domain of DROSHA have been found in ~12% of favorable histology 
Wilms tumors.16 In the majority of DROSHA-mutant tumors, a recurrent mutation 
(E1147K) affecting a metal ion binding residue of the RNase IIIb domain was found. 
These somatic mutations act through a dominant-negative mechanism to impair 
processing of primary miRNAs, resulting in the reduction of global miRNA 
biogenesis.16-17,32 Gene and miRNA expression profiling has demonstrated that the 
miR-200 family is one of the subsets of miRNAs reduced in tumors, correlating with 
downregulation of genes involved in the mesenchymal to epithelial transition.  
Given the multistep progression of miRNA processing, it is not surprising that 
other genes involved in the stepwise progression of miRNA biogenesis have also 
been found somatically mutated in Wilms tumors. Mutations in DGCR8, a component 
of the microprocessor complex and cofactor of DROSHA, as well as XPO5 and 
TARBP2 have also recently been identified through next-generation sequencing 
efforts.16 Occasionally, mutations in several miRNA pathway genes have been found 
in the same tumor providing multiple hits to the miRNA pathway and underscoring the 
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importance of a normal functioning miRNA processing system. One component of the 
miRNA pathway that is mutated less frequently than DROSHA and DGCR8 is 
DICER1. 
 
4.1.3. DICER1 and DICER1 Syndrome 
 One of the enzymes at the center of the micro RNA biogenesis pathway is 
DICER1. Located on chromosome 14q32.13, DICER1 is a large multidomain enzyme 
containing twenty-six coding exons (Figure 19). DICER1, functioning downstream of 
DROSHA and DGCR8, encodes a cytoplasmic endoribonuclease essential for the 
generation of mature microRNAs from pre-miRNAs.88 In order for DICER to perform 
its ribonuclease activity, the protein folds such that the RNase IIIa and IIIb domains 
form an intramolecular dimer, creating a catalytic core whereby each domain cleaves 
one strand of the double-stranded pre-miRNA substrate. The RNase IIIa and IIIb 
domains cleave the 3p and 5p miRNA strands, respectively. This requires proper 
positioning of the RNA substrate over the catalytic domains, which is accomplished by 
a number of DICER domains. Among these are the platform and PAZ domains, which 
recognize the 5’ terminal phosphate and 3’ 2-nucleotide overhang of the pre-miRNA, 
respectively. Additionally, the DExD/H box helicase domain is thought to form a claw-
like structure to clamp down on the loop structure of the substrate, ultimately allowing 
correct positioning of the dsRNA along the  connector helix, where a positively 
charged surface interacts with the phosphate backbone residues of the pre-miRNA. 
Following the favorable interaction between the pre-miRNA and DICER, cleavage of 
each strand takes place at a fixed distance from the terminal ends of the pre-miRNA, 
generating a mature miRNA of 22 nucleotides.  
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 Dicer1 knockout in the mouse is embryonic lethal, suggesting that loss of 
Dicer1 activity is incompatible with normal development. Dicer1 is expressed in the 
fetal kidney, where it is critical for renal morphogenesis. Particularly, kidney-specific 
ablation of Dicer1 in early metanephric mesenchymal cells results in renal dysgenesis 
and apoptosis. These mice show nephron progenitors that are initially correctly 
specified with normal ureteric bud outgrowth, however subsequent ureteric branching 
and nephron differentiation do not occur.70  
Most DICER1 mutations identified in Wilms tumors to date are somatic 
alterations, although germline mutations are occasionally observed.89-91 Mutations in 
DICER1 were first identified to cause familial pleuropulmonary blastoma in 2009.92 
Since then, biallelic mutations have been identified in a variety of tumor types, 
including Wilms tumors, which suggests a “two-hit” tumor suppressor model.91 In this 
model, germline mutations, frequently truncating, are inherited, whereas somatic 
missense mutations occurring at hotspots within the RNase IIIb domain result in a 
second hit contributing to the development of a well-defined tumor predisposition 
syndrome referred to as DICER1 Syndrome.89 This is a pleotropic cancer syndrome 
which commonly includes  phenotypes such as pleuropulmonary blastoma, cystic 
nephroma, ovarian sex cord-stromal tumors, and multinodular goiter, as well as less 
frequent phenotypes including differentiated thyroid carcinoma, pituitary blastoma, 
pineoblastoma, and Wilms tumor, among others. Penetrance of the various 
phenotypes of DICER1 Syndrome is incomplete, with more than half of mutation 
carriers exhibiting none of the phenotypes associated with the syndrome.  
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4.2. Materials and Methods 
4.2.1. WTX593 and WTX279 Families 
 Following informed consent, blood was drawn and DNA isolated from affected 
individuals and/or obligate carriers from 48 WT families. Genomic DNA from two of 
these families was then used for whole genome sequencing. These two families did 
not carry WT1, WTX, CTNNB1 or TP53 mutations. The first family (WTX593) 
consisted of four individuals diagnosed with unilateral WT, with the age of diagnosis 
ranging from 38-57 months. Additionally, thyroid colloid cysts, multinodular goiter 
(MNG), and kidney multi colloid cysts, and/or pulmonary cysts were noted in family 
medical records. Fresh-frozen Wilms tumor was available from one individual. 
In the second family (WTX279) two individuals were diagnosed with WT, one at 
3.5 years of age and the other at 13 years of age. The latter, the proband, relapsed 
after two years and was found by CT scan to have two small pulmonary nodules 
which, however, were too small to biopsy. Additionally the father of the proband had 
one kidney removed at 3 years of age due to a suspected, but poorly documented, 
premalignant condition.  
Whole genome sequencing of peripheral blood DNA was carried out on two 
affected individuals and one obligate carrier individual in the WTX593 family as 
described in chapter 2. 
 
4.2.3. Protein modeling of DICER1 mutation 
Protein modeling of the DICER1 G803R mutation was performed using the 
Protein Homology/analogy Recognition Engine version 2.0 (Phyre2; 
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http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) following the 
manufacturer’s instructions.  
 
4.2.4. Mutation analysis of DICER1 in familial Wilms tumor. 
Sanger sequencing was performed (as described in chapter 2) to confirm the 
DICER1 variant detected by WGS and to assess 47 additional families for mutations 
in the same DICER1 exon (exon 15) or seven other DICER1 exons (exons 8, 9, 13, 
14, and 24-26) at which mutations have been reported in WT. Primer sequences are 
listed in Table 10. 
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!
Forward!primer! Reverse!primer!
DICER1!exon!7! TTCTCACTACTGCAGTATTGATACCTT! GAGCCGCATTAAGCATATTTTC!
DICER1!exon!8! AAATCCCAGTTAAACCCCAC! TCACATCACAACACAGGACG!
DICER1!exon!9! TAAATCACCGTCGCCAAATC! AAATCACTCTACAGCTACCTCATGG!
DICER1!exon!13! TTTTACTAGGCAGGACTTTTAAAGATG! AAGTGTTCATGGTGCATGATTC!
DICER1!exon!14! TTTGCAGTCCAGCTCATATTG! AAGCTGTGAATCGGAGAAAG!
DICER1!exon!15! CTGAGATCCGCTGACTTAC! CCCCTCAAAATTAACAGGTA!
DICER1!exon!24! TGTGGGGATAGTGTAAATGCTTC! TGCCGTCAGAACTCTGAAAC!
DICER1!exons!25@!
26! TGGACTGCCTGTAAAAGTGG! TGAACTTTTCCCCTTTGATG!
 
 
Table 10. DICER1 exon primer sequences for Sanger sequencing 
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4.3. RESULTS 
4.3.1. Whole genome sequencing identifies DICER1 as candidate predisposition 
gene. 
Blood DNA from three affected/obligate carrier individuals from the WTX593 
family was used for whole genome, paired-end sequencing to identify the Wilms 
tumor predisposing alteration in the family (Figure 20a). The mean whole genome 
sequencing coverage across all genes for the three individuals sequenced (Figure 
20b) ranged from 32-45X, with 97% coverage of genes at >10X depth. Variants 
shared by all three individuals were identified and filtered based on their allele 
frequency reported in the general population (<1%), with novel variants occurring in 
protein coding regions assigned a higher priority for investigation. Of the 113 variants 
left after filtering, a novel missense mutation in DICER1 was of greatest interest 
because mutations in this gene have recently been found in DICER1 syndrome 
families which include a member with WT.16 The identified mutation (c.2407G>A, 
chr14:!95574690, hg19) occurred in exon 15 of DICER1 and results in a glycine to 
arginine substitution at codon 803 (G803R) (Figure 21). The variant was not present 
in the Single Nucleotide Polymorphism database (dbSNP) 
(http://www.ncbi.nlm.nih.gov/SNP), NHLBI Exome Variant Server 
(http://evs.gs.washington.edu/EVS) nor 1000 Genomes database. This alteration was 
predicted to be deleterious by SIFT, PolyPhen2 and MutationTaster (0, 0.991, 0.999, 
respectively). The mutation occurred at an evolutionary conserved amino acid residue 
(PhyloP – 0.999) within the platform domain of DICER1, which is involved in  
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Figure 20a. WTX593 pedigree. Of the four unilateral Wilms tumor cases in the family, 
blood was obtained from two. Whole genome sequencing (indicated by red boxes) 
was performed on these family affected family members (V-1, V-2), as well as an 
obligate carrier (II-13) 
 
 
 
SUMMARY OF VARIATION 
Individual   V-2   V-1   III-13  
Gender   Female  Male   Male 
Coverage    44.5    32.3   41.5 
 
SNPs    3,766,935  3,683,999  3,680,540 
Insertions   335,055  318,537  317,365 
Deletions   350,486  332,452  335,863 
 
Shared, Novel Variants 
Synonymous SNPs  60 
Nonsynonymous SNPs 80 
Nonsense SNPs  1 
Insertion   46 
Deletion   32 
 
Figure 20b. The coverage and total number of variants across the whole genome for 
each individual sequences. This includes data for calls where Q score >20. 
Additionally, the number of shared, novel exonic variants are listed. 
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Figure 21. Next-generation sequenced reads visualized with IGV showing the 
DICER1 G803R variant in each family member. The variant is present in ~50% of 
sequence reads. 
 
 
 
 
 
         V-2  V-1  III-13   
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the recognition of the 5’ phosphate group of pre-miRNAs, and between residues that 
interact with the 5' phosphate of miRNAs.21 
DICER1 is actively expressed in early renal progenitor cells (Figure 22) and 
knockout studies show a failure of nephron differentiation, suggesting DICER1 activity 
is required for kidney development. 
 
4.3.2. DICER1 G803R cosegregates within the “DICER1 Syndrome” family 
We confirmed the alteration by Sanger sequencing and extended our analysis 
to additional family members to estimate the penetrance of the variant in the family. It 
was noted that other phenotypes of DICER1 syndrome were present in some family 
members. In total, we detected the G803R mutation in eleven family members, some 
of whom displayed one or more of the phenotypes associated with familial DICER1 
syndrome, including lung cysts, thyroid cysts, MNG, cystic nephroma and WT (Figure 
23a).  
 
4.3.3. Loss of wildtype allele observed in tumor 
The one tumor available for study was found to be homozygous for the G803R 
mutation by Sanger sequencing (Figure 23b). Such homozygosity for a germline 
DICER1 mutation has not previously been reported for Wilms tumors, although this 
has been observed in cases of DICER1-associated pineoblastoma and pituitary 
blastoma.99,100 Typically in Wilms tumors arising in individuals with a DICER1 
truncating mutation, somatic hotspot mutations occurring within the RNase IIIb 
domain have been described. 
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Figure 22. DICER1 expression in the fetal kidney 
using gudmap.org. DICER1 is actively expressed in the 
metanephric  mesenchyme and ureteric bud at E11.5.  
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Figure 23. DICER1 G803R co-segregates with the affected/obligate carrier status 
with the family. “+” indicates the individual carriers the G804R variant. “-“ indicates 
family members who do not carry the variant. Other DICER1 Syndrome phenotypes 
are listed on the pedigree. WT: Wilms tumor, TC: thyroid cysts, MNG: multinodular 
goiter, BKT: benign kidney tumor. Sanger sequencing of the only tumor available from 
the family shows loss of the wildtype allele.  
 
 
 
 
A 
B 
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3.3.4. Protein modeling of DICER1 mutation suggests a functional effect 
Protein modeling using the Protein Homology/analogy Recognition Engine v2.0 
(Phyre2; www.sbg.bio.ic.ac.uk/phyre2) suggests that the G803R mutation disrupts an 
alpha helix at the end of the platform domain, potentially altering the 5’ terminal 
phosphate recognition pocket of the domain (Figure 24). Residues within this pocket, 
and adjacent to the G803R variant, interact with the terminal phosphate group on the 
5p miRNA strand. This is consistent with the SIFT, PolyPhen and Mutation Taster 
scores which predict the substitution of a glycine for an arginine at codon 803 is 
deleterious. 
 
 
 
Figure 24. Protein modeling performed in Phyre2. Shown is a protein model of the 
platform and PAZ domains of wildtype DICER1 (left) and G803R (right). Highlighted in 
blue are the differences between each model, due to the introduction of an arginine 
residue at codon 803. This results in the alteration of an alpha-helix within the 
platform domain. 
 
Wildtype G803R 
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4.3.5. DICER1 mutation analysis in familial Wilms tumor 
Sanger sequence analysis of one member each of 47 additional WT families 
revealed that one carried a novel frameshift mutation (c.2399delG, p.R800fsX5) in the 
same exon (exon 15) as that in WTX593 (Figure 25a). This mutation also occurs in 
the evolutionarily conserved platform domain, was not present in the 1000 Genomes 
database, dbSNP or the Exome Variant Server, and segregates with the affected 
status in the family (Figure 25b). It is predicted to encode a truncated protein lacking 
an intact platform domain and the remaining half of the protein, including the PAZ 
domain and the RNase IIIa and IIIb domains. Tumor samples were not available for 
this family; LOH could not be assessed.  
Sanger sequencing of seven other exons in which DICER1 mutations have 
been previously identified in WT cases (exons 8, 9, 13, 14, 24, 25, 26) was also 
performed in 46 other Wilms tumor families. No germline variants were observed in 
these families.  
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 II-4 
 
 
 
 II-3 
 
 
 
 III-3 
 
 
 
 
 
Figure 25a. Identification of an additional germline DICER1 mutation in a Wilms 
tumor family. The variant is a frameshift deletion predicted to result in the premature 
truncation of the protein. Sanger sequencing showed the variant segregates with the 
affected status in the family. 
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4.4. DISCUSSION 
 Mutations in miRNA pathway genes have recently been identified in approximately 
15% of favorable histology Wilms tumors.17 The majority of these are somatic 
mutations clustering at RNase domains of DROSHA and DICER1, two 
endoribonucleases critical for proper miRNA maturation. While the vast majority of 
these are somatic mutations, germline mutations in DICER1 have been identified in 
several tumor types and are associated with a pleiotropic tumor predisposition 
syndrome called DICER1 syndrome. In this syndrome, inherited truncating mutations 
and somatically acquired missense mutations occurring at or adjacent to metal-ion 
binding residues (D1705, D1709, D1713,G1809, E1813) within the RNaseIIIb domain 
are typically found in families. The result of these biallelic mutations is impaired 5p 
miRNA biogenesis, including major miRNA families such as let-7 and miR-200, while 
3p miRNA levels are unaltered. This reduction of 5p miRNAs is thought to contribute 
to the development of DICER1-associated phenotypes through the deregulation of 
target genes, including members of the miR-200 family with roles in the mesenchymal 
to epithelial transition critical for normal kidney development. 
 To date, only six DICER1 families with a member diagnosed with WT have been 
reported in the literature and each of these has only one WT case. In these rare 
families, similar to non-WT DICER1 families, germline DICER1 nonsense mutations 
were observed, along with an additional somatic missense mutation occurring in trans 
in the tumor.16 In our study, we identified two Wilms tumor families with novel germline 
DICER1 mutations. Both germline mutations occurred in the platform domain, which 
has a role in recognizing the terminal phosphate group of the 5p strand of pre-
miRNAs for correct positioning over the RNase III domains for cleavage (Figure 26).  
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Previous studies have shown mutations in this domain result in reduced processing 
efficiency of mature miRNAs.21 Consistent with what has been observed in other 
DICER1 families, the novel mutation (R800Xfs5) we identified in WTX279 is predicted 
to result in the premature truncation of the protein. WTX279 is a small WT family, and, 
while it is not known whether individuals in this family displayed phenotypes 
associated with DICER1 syndrome, pulmonary nodules were detected in the proband 
by CT scan. These nodules, however, were too small for biopsy and it is unknown if 
they were WT metastases or were similar to the cystic pulmonary phenotype that is 
observed in DICER1 Syndrome. Uniquely, multiple family members were diagnosed 
with Wilms tumor in this small family; DICER1 families reported to date have only a 
single WT case. 
 The diagnosis, not only of Wilms tumor, but also of MNG, lung cysts, thyroid and 
kidney cysts in the WTX593 family is consistent with this being a “DICER1 syndrome 
family”. In total, 11 individuals in this family were found to carry the germline mutation, 
with 2/11 diagnosed with only WT, 2/11 diagnosed with WT and lung cysts, 2/11 with 
thyroid cysts, 1/11 with MNG and 1/11 with kidney cysts. In addition to the presence 
of multiple WT cases, WTX593 is unique on several counts. First, it carries a germline 
DICER1 missense mutation rather than a frameshift or nonsense mutation. Only one 
other family (in which only multiple nodular goiters are observed) is reported to have 
sustained a germline missense mutation. Interestingly, this mutation (Ser839Phe) also 
occurred in the platform domain. The G803R mutation we identified in WTX593 is 
predicted to be deleterious by a number of functional prediction algorithms and occurs 
at an evolutionarily conserved amino acid residue, suggesting this mutation is 
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functionally significant. Moreover, protein modeling suggests this alteration disrupts 
an alpha helix in the platform domain. 
 Secondly, the germline G803R mutation in WTX593 was reduced to homozygosity 
in a tumor from a family member. In contrast, almost all the second, somatic 
mutations observed in tumors from individuals with germline DICER1 mutations are 
missense mutations that occur in the RNase IIIb domain of DICER1. To date, loss of 
heterozygosity with retention of the germline mutation has only been reported in two 
DICER1-associated phenotypes – pineoblastoma and pituitary blastoma.99,100 LOH 
has not previously been reported in Wilms tumors with DICER1 mutations.  
 Additionally, like WTX279, WTX593 is a family where a germline DICER1 mutation 
results in multiple cases of Wilms tumor. The penetrance of the G803R allele with 
respect to Wilms tumor is notably much higher than other germline DICER1 mutations 
(which, as noted above, are almost invariably truncating mutations). The basis for this 
increased penetrance is not known. Obviously, ascertainment bias is a factor as the 
families being studied were originally selected due to the occurrence of two or more 
Wilms tumor cases. However, is it still curious that families ascertained for PPB and 
other, DICER1-associated phenotypes only rarely have a member with Wilms tumor 
(much less two or more), while in both families reported here, the DICER1 mutations 
were relatively highly penetrant with respect to Wilms tumor.  
 Interestingly, while the penetrance of the two novel DICER1 mutations we 
identified in these two families was unusually high, the ages at which individuals in 
these families were diagnosed with Wilms tumor was notably older than average 
Wilms tumor cases in general. The median age of diagnosis for unilateral Wilms 
tumor overall is ~39 months of age while that of unilateral cases in familial context is 
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35 months. Wilms tumor families, however, greatly vary with respect to age at 
diagnosis, with some families exhibiting typically younger ages, while other families 
consist of cases with later than average ages of onset. The observation that both 
families carrying DICER1 mutation reported here have members diagnosed at late 
ages suggests that this may be a common feature of DICER1-related Wilms tumor.  
 Our data demonstrates that mutation of DICER1 is associated with the 
development of familial Wilms tumor and describes interesting and novel findings with 
respect to the missense mutation we identified. Our identification of germline DICER1 
mutations in 4% of Wilms tumor families is consistent with the recent reports 
describing mutations in multiple members of the miRNA biogenesis pathway in 
sporadic Wilms tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!! 95!!
CHAPTER 5: Identification of a recurrent 570kb duplication on chr2p 
encompassing NBAS, DDX1, MYCN and MYCNOS in Wilms tumor 
families. 
 
5.1. INTRODUCTION 
Copy number variation of specific regions of the genome have been identified 
in sporadic Wilms tumors using array comparative genomic hybridization (aCGH) and 
SNP arrays.93 These include losses at 17p, 1p, 16q and gains at 1q, 8, 12, suggesting 
that these regions harbor genes that play a role in Wilms tumorigenesis. After 
sequencing the whole genome of two individuals from a large Wilms tumor family, we 
detected a 570kb duplication on chr2p24 which predisposes to the development of 
Wilms tumor. This region includes 4 genes; NBAS, DDX1, MYCN and MYCNOS, and 
was initially selected for further investigation due to the established role of MYCN in 
both development and Wilms tumorigenesis. 
 
 
5.1.1. MYCN functional activity and it’s role in kidney development 
MYCN belongs to the MYC family of transcription factors with well-documented 
roles in the control of cell proliferation and differentiation.94 MYCN is a conserved 
basic helix loop helix transcription factor that forms a heterodimeric complex with Max 
and binds to a CANNTG E-box consensus sequence found upstream of promoter 
target sequences. This complex acts as a transcriptional regulator by activating or 
repressing hundreds of target genes through the interaction with various nuclear 
protein complexes.  
MYCN expression, primarily detected in the developing embryo, is absent from 
adult tissues suggestive of a principal responsibility in mediating embryonic 
development. Indeed, experiments in mice have shown that MYCN is essential for 
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both neurogenesis and nephrogenesis. Homozygous ablation of MYCN in mice 
results in embryonic lethality at E10 due to defects of the central nervous system, 
kidney, lung, gut and heart. In the developing brain, MYCN is involved in the induction 
of a stem-cell like state by blocking differentiation and activating the pluripotency 
factors, KLF2, KL4 and LIN28B. Moreover, reduction of MYCN expression levels in 
neuroblastoma cell lines leads to induction of a differentiated phenotype. MYCN is 
particularly interesting with respect to Wilms tumor biology, as it is highly expressed at 
early stages of development in the metanephric mesenchyme. Its expression 
becomes increasingly restricted as embryonic development proceeds and is 
undetectable in adult human kidney tissue. Reduced or loss of MYCN expression in 
cultured embryonic kidneys results in renal hypoplasia due to a decrease in cell 
proliferation in ureteric bud and mesenchymal tissues, while apoptosis was not 
affected.38 Thus, MYCN expression in the embryonic kidney is critical for 
nephrogenesis. 
 
 
5.1.2. MYCN alterations in Wilms tumors 
5.1.2.1. Amplification 
Amplification of one particular region on chromosome 2p24, including the 
MYCN locus, has been described in several pediatric cancers, including Wilms 
tumor.18,33-36 In 10% of Wilms tumor cases, increased MYCN copy number and 
expression has been described, suggesting this region has a functional role in the 
development of Wilms tumors. MYCN is also somatically amplified in other childhood 
cancers such as neuroblastoma, medulloblastoma, retinoblastoma, alveolar 
rhabdomyosarcoma, and astrocytoma. Of these, MYCN has been most extensively 
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studied in the context of neuroblastoma, where it is amplified in roughly 25% of cases 
and is associated with poor prognosis. In Wilms tumors, somatic MYCN amplification 
has primarily been observed in the context of sporadic cases. However, a germline 
chr2p24 duplication encompassing MYCN and detected by array comparative 
genomic hybridization (aCGH) was reported in one family with a history of 
nephroblastomatosis and Wilms tumor.95 This duplication was subsequently observed 
in an additional patient with bilateral Wilms tumor from an independent study, as well 
as in our analysis (described below).  
 
5.1.2.2. MYCN is often coamplified with other flanking genes  
When MYCN amplification has been observed in both neuroblastoma and 
Wilms tumor, it frequently includes additional neighboring gene(s), including orthinine 
decarboxylase (ODC), syndecan-1, ribonucleotide reductase (RRM2), ALK, DDX1, 
NBAS, and MYCNOS. Genes coamplified with MYCN in Wilms tumor cases include 
the 5’ region of NBAS, as well as the complete coding sequences of DDX1 and 
MYCNOS. For example, MYCN and DDX1 were both somatically amplified in a Wilms 
tumor-derived xenotransplanted cell line.96 Moreover, germline duplication of a 570kb 
region including these genes has been recently observed in Wilms tumor patients.  To 
date, DDX1 amplification without concomitant MYCN amplification has not been 
described, suggesting MYCN as the primary gene responsible for tumorigenesis. 
Interestingly, a genome-wide association study (GWAS) identified a significant 
association signal within this duplicated region when examining 1,488 Wilms tumor 
samples.97 Collectively, this suggests germline copy number alterations in this region 
could predispose to Wilms tumor.  
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DDX1, a DEAD box helicase that has roles in the alteration of RNA secondary 
structure, is frequently coamplified with MYCN (DDX is 340kb 5’ of MYCN, and is 
telomeric of MYCN on 2p24). Like MYCN, DDX1 is also strongly expressed during 
early kidney development (Figure 27). A recent report described a nuclear role of 
DDX1, where it acts as a cofactor of DROSHA in ovarian cancer cells in the 
recruitment of a specific subset of pri-miRNAs for processing.98 This provides an 
intriguing connection to the miRNA biogenesis pathway, which has very recently been 
implicated in Wilms tumor development.  
 
 
5.1.2.3. Point mutations 
Not only is MYCN amplified in sporadic Wilms tumors, but a somatic 
heterozygous point mutation (c.131C>T, p.P44L) within the aurora kinase A domain 
has recently been identified in ~4% of Wilms tumors by several groups using next-
generation sequencing.18 This variant was somatic in all cases and is believed to be a 
gain of function mutation due to its occurrence at a highly conserved amino acid 
residue. Tumors carrying the P44L mutation do not appear to have morphologically 
distinguishing features to suggest the alteration results in a specific histology or 
clinical stage. In one study, 40% of P44L-mutant tumors also had modest MYCN 
amplification. Interestingly, a bilateral Wilms tumor case described separate MYCN 
alterations in one patient: an MYCN point mutation (P44L) in one tumor with MYCN 
amplification in the contralateral tumor, suggesting multiple mechanisms of MYCN 
dysregulation in Wilms tumor development.18 
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5.2. Materials and Methods 
5.2.1. WTX614 and WTX637 families 
 Following informed consent, blood was drawn and DNA isolated from members 
of the WTX614 and WTX637 families. Mutation analysis of WT1, WTX and CTNNB1 
revealed no germline mutations in the affected individuals, thus the predisposition 
gene mutation was determined to be unknown. The WTX614 family consists of eight 
Wilms tumor cases, with the age of diagnosis ranging from 14 to 204 months. 
Additional phenotypes in the family included medulloblastoma and astrocytoma. 
Tumor samples were not available for these patients for further analysis. The 
WTX637 family contained five Wilms tumor cases, with the age of diagnosis ranging 
from 5 to 72 months. Tumor samples were also not available from these family 
members. 
Whole genome sequencing of peripheral blood DNA was carried out on two 
affected individuals in the WTX614 family (IV-3 and III-11) as described in chapter 2.  
 
5.2.3. Copy number analysis using qPCR 
Copy number variation was confirmed using a SYBR green qPCR assay with 
primers targeting DDX1 and MYCN. Primer sequences are listed in Table 11. 
Genomic DNA, gene-specific primers and SYBR green were analyzed using the 
Applied Biosystems 3730 real time machine. Additionally, primers targeting ** on 
chromosome 5 (one of the regions where copy number alterations are rarely observed 
in Wilms tumor) served as a control.  
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Forward primer Reverse primer 
MYCN GAGAGGACACCCTGAGCGATT CAAGACATACGAGCACTAACAAAGG 
DDX1 CCCAACTGATATCCAGGCTGAA AGTGTGTCCCCAGCTACCAATC 
 
TABLE 11. qPCR primer sequences for MYCN and DDX1 copy number analysis. 
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5.3. Results 
5.3.1. Whole genome sequencing identifies recurrent 570kb duplication on 
chr2p  
We sequenced the whole genome of two affected individuals in a large, multi-
generation WT family (Figure 27a) consisting of 8 WT cases to identify the 
predisposing alterations contributing to the development of FWT.  The mean coverage 
across the genome was 30X for IV-3 and 33X for III-11, with 96.5% and 96.8% of 
positions covered by at least 10X (Figure 27b).  Comparison of shared variants 
resulted in the identification of 344 novel, exonic variants (excluding synonymous 
variants). These genes were assessed for known developmental or differentiation-
related roles in the embryonic kidney. After surveying single nucleotide variants within 
the family, we were not able to identify a convincing candidate gene for further 
evaluation. Although several genes appeared to be potential candidates based on our 
criteria for identifying predisposition genes, none of them had a clear role in renal 
morphogenesis. Next, we examined shared structural variants, including large 
insertions, deletions, duplications, inversions and translocation calls generated using 
CASAVA v.1.8. This analysis examined read depth to identify regions where copy 
number gains or losses were suspected due to read density deviation from the 
average coverage calculated across the whole genome. This resulted in the 
identification of a 570kb duplication on chromosome 2p24 encompassing 4 genes:  
NBAS, DDX1, MYCN and MYCNOS (Figure 28). This duplication was initially selected 
for further investigation because MYCN has previously been shown  
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SUMMARY OF VARIATION 
Individual     IV-2   III-11    
Gender     Male   Male    
Coverage      33.6    30.5    
 
SNPs      3,673,595  3,676,171   
Insertions     315,113  317,527   
Deletions     329,229  327,892   
 
Shared Novel Variants 
Synonymous SNPs    83   
Nonsynonymous SNPs   94   
Stop Gain SNPs    0    
Stop Loss SNPs    0    
Insertion     37    
Deletion     22    
   
 
Figure 27. WTX614 pedigree. Individuals whose whole genomes were sequenced 
are indicated by red boxes. The summary of genetic variation is also listed including 
data for calls where Q score >20. 
 
 
 
 
 
A 
B 
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Figure 28.  The chr2p24 570kb duplication includes four genes: NBAS, DDX1, MYCN 
and MYCNOS. Coverage plots for the boundaries of the duplication are shown from 
each individual sequenced. Copy number variation was identified after extracting read 
counts for each position across the whole genome, segmentation of the genome into 
50bp segments, and calculating read depth within the 50bp segments compared to 
average coverage across the whole genome. Regions with increased or decreased 
read density compared to the whole genome were classified as gains or losses, 
respectively. 
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to be amplified in ~10% of Wilms tumors, with germline duplication of this gene 
potentially serving as a mechanism for increased expression. 
 
5.3.2. Duplication co-segregates with affected/obligate carrier status  
Quantitative PCR (qPCR) was used to confirm the duplication using primers 
targeting an exonic region of DDX1 and MYCN. Extending this analysis to additional 
family members revealed the duplication segregates with the affected/obligate carrier 
status and is absent in all spousal controls tested (Fig29). In total, 9 members of the 
family carried the duplication and 7, including 4 spousal controls, did not carry the 
duplication. Each affected and obligate carrier individual in the family, for whom we 
had blood samples for, carried the duplication. 5 of 9 (55%) carriers developed Wilms 
tumor, consistent with the characteristic reduced penetrance of Wilms tumor in 
families. 
 
5.3.3. Copy number analysis in familial Wilms tumor identified second family 
with co-segregating duplication 
Additionally, we assessed this region in one member from each of 47 other WT 
families to determine the frequency of the duplication in familial WT (Figure 30).  This 
analysis resulted in the identification of an additional family (WTX279) that harbors the 
570kb duplication.  The duplication was found to segregate with the affected/obligate 
carrier status in WTX279 and is absent in spousal controls (Fig30). 4/6 (66%) carriers 
in the family developed Wilms tumor. In total, we detected this recurrent duplication in 
2/47 (4.2%) WT families.  
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Figure 29. Copy number was confirmed using qPCR targeting DDX1 and MYCN. The 
570kb duplication on chr2p24 cosegregates with the affected/obligate carrier status in 
the family. + indicates carriers of the duplication, - indicates those members who don’t 
carry the duplication.  
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Figure 31. Copy number was confirmed using qPCR targeting DDX1 and MYCN. The 
570kb duplication on chr2p24 cosegregates with the affected/obligate carrier status in 
the WTX279 family. + indicates carriers of the duplication, - indicates those members 
who don’t carry the duplication.  
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5.4. Discussion 
This chapter describes two Wilms tumor families with a chr2p microduplication 
that cosegregates with the affected/obligate carrier status in each family. The 
identification of multiple families harboring this duplication from our study and others, 
as well as previous reports of amplification of MYCN in approximately 10% of Wilms 
tumors suggests that copy number variation of this region is associated with the 
development of Wilms tumor. Further support comes from recent studies that 
described a recurrent MYCN point mutation (P44L) in ~4% of Wilms tumors, which 
has also been identified previously in neuroblastoma. This somatic recurrent mutation, 
occurring at a highly conserved residue, has been suggested to be an activating 
mutation, although studies have not functionally validated its significance. It is likely 
that an activating mutation in MYCN could have the same functional effect as MYCN 
amplification on downstream targets. Interestingly, this recurrent point mutation 
occurs within the aurora kinase A interaction domain which, when bound to MYCN, is 
involved in insulating MYCN from FBXW7-mediated degradation. FBXW7, an element 
of an E3 ubiquitin ligase complex involved in the direct targeting of MYCN for 
ubiquitylation and proteasome-mediated degradation, is  somatically mutated in 
approximately 4% of Wilms tumors. Therefore, gain of MYCN or the loss of genes 
involved in it’s regulation (FBXW7) potentially have overlapping downstream functions 
allowing exploitation during kidney development to give rise to Wilms tumors. 
Interestingly, alterations in MYCN copy number have previously been found in 
other childhood cancers in addition to Wilms tumor. These include retinoblastoma, 
neuroblastoma, astrocytoma, and medulloblastoma, where MYCN gain is associated 
with an adverse outcome. In the WTX614 family, two individuals carrying the 
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duplication were also diagnosed with medulloblastoma and astrocytoma.  There has 
been no evidence reported previously suggesting a germline duplication 
encompassing DDX1 and MYCN predisposes to these tumor types. However, two 
reports have described somatic amplification of this region in both medulloblastoma 
and astrocytoma tumors, although this appears to be a rare event. While 
constitutional MYCN duplications have been found to predispose individuals to 
neuroblastoma, none of the patients in this study who carry the germline duplication, 
to our knowledge, developed neuroblastoma.  
The mechanism of the reduced penetrance in these families is not known, and 
tumor tissue was unavailable from both families carrying the germline duplication, 
eliminating the possibility of molecular analysis of tumors for additional alterations. 
Intriguingly, a patient carrying a germline partial 2p trisomy including MYCN 
developed a neuroblastoma with dramatic amplification of MYCN, suggesting the 
germline duplication might predispose to further somatic amplification. While we can’t 
rule out this scenario in the Wilms tumor patients from our study, a recent report 
describing a bilateral Wilms tumor patient carrying this chr2p germline duplication 
showed no further amplification of MYCN in the tumor sample. Another possibility for 
the reduced penetrance is that, while the chr2p duplication predisposes to Wilms 
tumor, additional mutation events at other loci have to occur during the progression of 
tumorigenesis. A previous report described a bilateral Wilms case in which one tumor 
contained an MYCN P44L mutation and TP53 V173L mutation, whereas the 
contralateral tumor contained MYCN amplification and a different TP53 mutation 
(I195T).18 This depicts a situation where MYCN amplification or mutation might not be 
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sufficient for tumor development without an additional mutation event occurring before 
or after MYCN alteration. 
Collectively, these data suggests that a constitutional chr2p duplication 
predisposes to Wilms tumor and patients carrying this duplication are at increased risk 
of developing Wilms tumor. Additionally, children with germline duplications of genes 
within this region potentially are at risk for the development of other tumors types, 
such as medulloblastoma and astrocytoma, although more studies are needed for 
definitive proof. The finding that MYCN might predispose to other tumor types in 
addition to Wilms tumor suggests that therapies targeting the MYCN pathway might 
be of significant value in other tumors as well. 
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CHAPTER 6: Summary and Future Directions 
6.1. Summary of Data 
The etiology of Wilms tumor is genetically heterogeneous. Like sporadic Wilms 
tumor cases, the genes and associated pathways contributing to familial Wilms tumor 
initiation and progression are diverse. The recent advancements in next-generation 
sequencing technologies have provided investigators with a high-throughput tool to 
investigate the genetic landscape of Wilms tumor, providing a glimpse into the 
complexity of the genetics of this childhood cancer. The research presented in this 
thesis is a perfect example of the characteristic genetically heterogeneous nature of 
Wilms tumor.  
Whole genome sequencing was performed using blood DNA from members of 
three Wilms tumor families. Bioinformatic filtering within each family identified shared 
variants for further consideration as candidate predisposition genes. DNA samples 
from an additional 45 Wilms tumor families were then analyzed for mutations in these 
candidate predisposition genes. Our analysis resulted in the successful identification 
of Wilms tumor predisposition genes in each family.  
We identified DICER1 exon 15 germline mutations in 2/48 (4%) Wilms tumor 
families. These novel mutations occurred at evolutionarily conserved amino acid 
residues within the DICER1 platform domain and were predicted to be deleterious. 
Interestingly, there were multiple cases of Wilms tumor within each family, which has 
not been observed in DICER1-associated Wilms tumors to date. Loss of the wildtype 
allele in one tumor was also an additional novel finding. Our data provides support 
that mutations in the miRNA biogenesis machinery can give rise to familial Wilms 
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tumors and is consistent with recent reports describing alteration of these genes in 
Wilms tumor. 
We also identified a germline 570kb duplication on chr2p24 in 2/48 (4%) Wilms 
tumor families. This duplication encompasses NBAS, DDX1, MYCN and MYCNOS. 
This duplication was previously observed in members of a multigenerational Wilms 
tumor family, as well as in a blood sample from a patient with bilateral Wilms tumor. 
MYCN and DDX1 amplification have been associated with sporadic Wilms tumors and 
our data reinforces the involvement of these genes in Wilms tumor development. We 
also observed other phenotypes, in addition to Wilms tumor, in members of the 
families that carry this duplication. As a result, this duplication might increase the risk 
of medulloblastoma and astrocytoma as well. 
Finally, we identified SPHK2 as a 19q candidate predisposition gene. The 
SPHK2 mutation we identified cosegregates in a large Wilms tumor family, has not 
been reported in variant databases, occurs at an evolutionarily conserved amino acid 
residue, and is functionally significant. This mutation alters SPHK2 subcellular 
localization and expression of target genes in MCF7 and M15 cell lines. Mutations 
identified in other Wilms tumor families and sporadic tumors provides additional 
evidence implicating this gene in familial Wilms tumor predisposition. Significantly, the 
identification of SPHK2 mutations in Wilms tumors opens up new avenues of research 
into how altered sphingolipid metabolism and signaling contribute to Wilms tumor 
development. Our data represents a significant advancement in understanding the 
etiology of familial Wilms tumor and associates alteration of new pathways with Wilms 
tumor development. 
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6.2. Future directions of research 
 The first step in understanding the mechanism of Wilms tumor development is 
to identify genes responsible for its formation. The goal of the research presented in 
this Thesis was to expand the etiology of Wilms tumor occurring in families, thus 
making a significant contribution to our understanding of cancer development in 
families. The next step will be to build on the novel findings presented here, in order to 
learn more about nephrogenesis, identify how these genes and their associated 
pathways contribute to aberrant differentiation and tumor formation, and recognize 
potential therapeutic targets. 
 DICER1 has been previously associated with Wilms tumor development in the 
context of DICER1 Syndrome, and progress is currently being made to understand its 
role, as well as that of the other miRNA biogenesis genes, in relation to Wilms tumor 
development. Potential future areas of research include characterization of the G803R 
mutation with respect to tumor formation. Possible experiments could include 
transfecting a kidney cell line with DICER1 wildtype and mutant constructs, followed 
by a miRNA cleavage assay and miRNA expression profiling to determine which 
miRNAs are deregulated. This would provide clues as to which genes are important in 
Wilms tumor development.  
 Recent studies are starting to uncover the significance of MYCN alterations in 
Wilms tumors and the mechanisms whereby they contribute to cancer. Interestingly, 
our data suggests that another gene within the duplicated region shared by affected 
family members might also contribute to Wilms tumor. DDX1 was recently shown to 
interact with Drosha and DGCR8, where it recruits specific subsets of pri-miRNAs for 
processing. Future research could focus on the specific pri-miRNAs that DDX1 binds 
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to, in order to 1) determine if DDX1 has a functional effect on Wilms tumor 
development and is not just amplified due to the proximity of MYCN, and 2) determine 
potential genes regulated by the DDX1-specific subset of miRNAs. 
 SPHK2 has never been implicated in Wilms tumor development. Consequently, 
how this gene functions with respect to kidney development and initiation of 
tumorigenesis is unknown, although our data and others have started to suggest a 
role in regulation of gene expression. Future research using mouse models could 
focus on how SPHK2 contributes to development of the embryonic kidney, as well as 
how mutating SPHK2 results in Wilms tumors. Specifically, introduction of 
SPHK2R101W into the mouse will provide a more complete picture of the involvement of 
SPHK2 in Wilms tumor development. Also, SPHK2 has not been extensively 
characterized and comparison of the SPHK2 amino acid sequence to other proteins 
has failed to identify functional domains. Future areas of research focusing on a 
comprehensive characterization of SPHK2 would greatly facilitate research into its 
functions. Additionally, further characterization of the known functions of SPHK2 
would clarify the apparent discrepancies reported in the literature with respect to 
localization, impact on proliferation and apoptosis. 
Finally, our whole genome sequencing analysis revealed the predisposing 
alterations in a small fraction of Wilms tumor families in our cohort. Whole genome or 
exome sequencing in other families will no doubt uncover other novel and unexpected 
causal genes. 
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